uracil has been researched along with Colorectal Cancer in 415 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer." | 9.69 | Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. ( Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2023) |
| "In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure." | 9.69 | Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study. ( Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023) |
| "A literature search in the Medline/PubMed and Embase databases was executed for finding series of trifluridine/tipiracil with bevacizumab in metastatic colorectal cancer." | 9.41 | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. ( Voutsadakis, IA, 2023) |
| "The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer." | 9.34 | Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ( Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A, 2020) |
| "A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile." | 9.30 | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. ( Bando, H; Horasawa, S; Kaneko, A; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Nakamura, Y; Shitara, K; Taniguchi, H; Tsuji, A; Yoshino, T, 2019) |
| "Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial." | 9.27 | Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. ( Ahn, JB; Bai, Y; Bi, F; Guo, W; Han, SW; Kim, TW; Li, J; Li, Q; Lin, D; Liu, T; Ma, D; Pan, H; Park, YS; Qin, S; Shen, L; Shi, C; Sriuranpong, V; Wu, C; Xu, J; Xu, R, 2018) |
| "In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies." | 9.27 | The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. ( Benavides, M; Ciardiello, F; Denda, T; Grávalos, C; Laurent, S; Lenz, HJ; Loehrer, P; Longo-Munoz, F; Makris, L; Mayer, RJ; Muro, K; Ohtsu, A; Portales, F; Siena, S; Tsuji, Y; Van Cutsem, E; Winkler, R; Yamaguchi, K, 2018) |
| "Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks, respectively, when compared with best supportive care alone (BSC)." | 9.27 | Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. ( Barzi, A; Cho, SK; Hay, JW, 2018) |
| "Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age." | 9.27 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. ( Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R, 2018) |
| "Oral uracil-tegafur and leucovorin (UFT/LV) therapy for elderly patients with metastatic colorectal cancer (mCRC) requires careful handling in Western countries because of a high incidence (≥20 %) of grade 3 diarrhea." | 9.20 | Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. ( Hyodo, I; Maeba, T; Matsumoto, T; Mizuta, M; Moriwaki, T; Nishina, T; Takahashi, I; Tsuji, A; Watanabe, R; Watanabe, Y, 2015) |
| "Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)." | 9.20 | Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015) |
| " We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin." | 9.20 | Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ( Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T, 2015) |
| "To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)." | 9.19 | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014) |
| "We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer." | 9.19 | [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer]. ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2014) |
| "To identify the genes and clinical parameters associated with efficacy of uracil and tegafur/leucovorin (UFT/LV) chemotherapy in colorectal cancer (CRC), we compared the levels of reduced folate in tumors between patients receiving LV and those not receiving LV (study I), and explored the changes in the expression levels of 14 genes after two weeks of UFT/LV chemotherapy in 73 patients with CRC (study II)." | 9.17 | Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer. ( Kamijo, A; Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2013) |
| "We have reported, in a randomized, controlled study, that tegafur-uracil(UFT)and protein-bound polysaccharide K(PSK)combination therapy significantly improves the 5-year disease-free survival rate and reduces the risk of recurrence compared to UFT alone for Stage II or III colorectal cancer." | 9.17 | [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K]. ( Hirai, K; Kawate, S; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D, 2013) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 9.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 9.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 9.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "A randomized controlled trial was conducted to determine whether pathologic necrosis in response to preoperative treatment with uracil-tegafur(UFT) could be used to identify patients with colorectal cancer most likely to benefit from postoperative adjuvant therapy with the drug." | 9.13 | Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. ( Fujii, M; Kochi, M; Takayama, T, 2008) |
| "To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer." | 9.13 | Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 9.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer." | 9.12 | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G, 2007) |
| "This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients." | 9.12 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| ") irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC)." | 9.12 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. ( Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D, 2007) |
| "To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer." | 9.12 | Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 9.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 9.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "To compare the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and leucovorin (LV) between Japanese patients and patients in the United States with previously untreated metastatic colorectal cancer." | 9.11 | Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ( Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004) |
| " infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC)." | 9.11 | Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. ( Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or metastatic colorectal cancer." | 9.10 | A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ( Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M, 2003) |
| "Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III." | 9.10 | Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. ( Ikeya, T; Kawashima, Y; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 9.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 9.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer." | 9.09 | Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. ( Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001) |
| "This phase I trial combining UFT plus oral calcium folinate (Orzel) with irinotecan (CPT-11) (Camptosar) for the treatment of patients with advanced or metastatic colorectal cancer will open shortly." | 9.09 | UFT plus calcium folinate/irinotecan in colorectal cancer. ( Twelves, C, 1999) |
| "To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)." | 9.09 | A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. ( Bonny, T; Bukowski, R; Burris, H; Hochster, H; Hohneker, J; Levin, J; Mani, S; O'Rourke, M; Schilsky, RL; Wall, JG, 2000) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 9.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "UFT (with leucovorin) and irinotecan both have single-agent activity in colorectal cancer, with non-cross-resistant mechanisms of action." | 9.09 | UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. ( Hill, M; Price, T, 2000) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 9.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 9.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 9.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 9.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking." | 9.05 | Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? ( Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q, 2020) |
| "Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)." | 9.01 | A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. ( Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019) |
| "Regorafenib and TAS-102 have shown to be superior to placebo in refractory metastatic colorectal cancer." | 8.98 | A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. ( Abrahao, ABK; Berry, S; Chan, KKW; Ko, YJ, 2018) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 8.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "5-Fluorouracil (5-FU) administered in several schedules since its introduction in 1957 continues to be an integral part of standard first-line therapy for colorectal cancer." | 8.82 | The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. ( Beretta, GD; Labianca, R; Milesi, L; Mosconi, S, 2004) |
| "Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer." | 8.31 | An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. ( Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023) |
| "Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC)." | 8.31 | Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. ( Ikoma, T; Matsumoto, T; Miura, K; Nagai, H; Takatani, M; Tsuduki, T; Watanabe, T; Yamamura, S; Yasui, H, 2023) |
| "Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the United States for treatment of refractory metastatic colorectal cancer (mCRC)." | 8.31 | A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. ( Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J, 2023) |
| "We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage." | 8.31 | A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023) |
| "Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting." | 8.31 | Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. ( Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D, 2023) |
| "The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial." | 8.31 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. ( Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023) |
| "In the pivotal RECOURSE trial, trifluridine/tipiracil improved survival outcomes in refractory metastatic colorectal cancer (mCRC), while demonstrating an acceptable toxicity profile." | 8.31 | The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. ( Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR, 2023) |
| "Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC)." | 8.31 | Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ( Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T, 2023) |
| "This study suggests that tegafur/uracil plus leucovorin is a feasible adjuvant chemotherapy regimen for patients with stage II colorectal cancer after curative surgical treatment." | 8.31 | Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan. ( Chen, HH; Fan, CW; Liao, CK; Liaw, YW; Liu, YH; Tseng, WK; Yeh, CY; Yu, YL, 2023) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 8.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 8.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 8.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 8.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
| "The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited." | 8.12 | Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. ( Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022) |
| "Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes." | 7.96 | Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. ( Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Hatachi, Y; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Oki, E; Sakai, D; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Tsuchihashi, K; Tsuji, A; Ueno, H; Yamashita, K; Yamazaki, K, 2020) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 7.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents." | 7.96 | Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. ( Burge, M; Chantrill, L; Gibbs, P; Pavlakis, N; Price, T; Shapiro, J; Sjoquist, K, 2020) |
| "Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments." | 7.96 | Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. ( Hatachi, Y; Kato, T; Kotaka, M; Ogata, M; Ogata, T; Satake, H; Tsuji, A; Yasui, H, 2020) |
| "The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated." | 7.96 | Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. ( Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Maeda, K; Nagahara, H; Ohira, M; Okazaki, Y; Shibutani, M; Wang, EN, 2020) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 7.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear." | 7.91 | Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ( Kadowaki, S; Kawakami, T; Kawamoto, Y; Komatsu, Y; Masuishi, T; Muranaka, T; Muro, K; Nakatsumi, H; Omae, K; Onozawa, Y; Tajika, M; Taniguchi, H; Yamazaki, K; Yasui, H; Yuki, S, 2019) |
| "Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer." | 7.91 | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance." | 7.91 | ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019) |
| "The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS)." | 7.91 | The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. ( Bonetti, A; Giuliani, J, 2019) |
| "This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment." | 7.88 | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. ( Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K, 2018) |
| " Clinical data were derived from the pivotal phase III (Randomized, Double-Blind, Phase 3 Study of TAS-102 plus Best Supportive Care [BSC] versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapies [RECOURSE]) and supporting phase II (J003-10040030) randomized controlled trial of trifluridine/tipiracil + BSC versus placebo + BSC, as well as the phase III Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (CORRECT) randomized controlled trial of regorafenib, and were extrapolated to estimate lifetime outcomes." | 7.88 | Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. ( Bullement, A; Fougeray, R; Hatswell, AJ; Underhill, S, 2018) |
| "The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients." | 7.88 | Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018) |
| "Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 7.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
| "Trifluridine/tipiracil (TFTD, TAS-102) is an orally administrated anti-cancer drug with efficacy validated for patients with metastatic colorectal cancer (mCRC)." | 7.85 | Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. ( Iimori, M; Kiniwa, M; Kitao, H; Kurashige, J; Maehara, Y; Morodomi, Y; Nakanishi, R; Nakashima, Y; Oki, E; Saeki, H; Sugiyama, M, 2017) |
| "We assessed the role of aspirin in patients with metastatic colorectal cancer who failed all previous treatments and were receiving capecitabine as a salvage option before the introduction of regorafenib and TAS-102." | 7.85 | The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. ( Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L, 2017) |
| "Regorafenib and trifluridine/tipiracil (TAS-102) both prolong survival for patients with refractory metastatic colorectal cancer." | 7.85 | Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. ( Ando, M; Fukutomi, A; Hamauchi, S; Ishihara, M; Kadowaki, S; Kito, Y; Komori, A; Machida, N; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Tajika, M; Tanaka, T; Taniguchi, H; Todaka, A; Tsushima, T; Ura, T; Yamazaki, K; Yasui, H; Yokota, T, 2017) |
| "This study sought to compare UFT/LV with capecitabine as adjuvant chemotherapy for the treatment of stage III colorectal cancer." | 7.83 | [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer]. ( Maruyama, T; Okumura, M; Sako, A; Ueda, K; Yasuda, K, 2016) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 7.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)." | 7.79 | Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)." | 7.79 | Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated." | 7.79 | A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "To identify useful predictive factors for the response to 5-fluorouracil (5-FU)/leucovorin (LV) and oral uracil and tegafur (UFT)/LV chemotherapy among patients with colorectal cancer, we investigated the association between the gene expression levels of pyrimidine and folate metabolism-related enzymes in colorectal cancer (CRC) tissues and the response to UFT/LV neoadjuvant chemotherapy." | 7.78 | Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. ( Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2012) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 7.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "To establish the sufficient therapy for elderly colorectal cancer patients, we retrospectively compared postoperative Tegafur/Uracil (UFT; Taiho Pharmaceutical Co." | 7.75 | Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. ( Takashima, S; Yoshitani, S, 2009) |
| " This study was conducted to examine changes in DPD activity in peripheral mononuclear cells (PMNC) during long-term treatment with oral uracil and tegafur (UFT) for colorectal cancer." | 7.74 | Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. ( Ishikawa, K; Kamijo, A; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2007) |
| "We report two cases of recurrent colorectal cancer in two patients who were treated successfully with a combined oral chemotherapeutic agent folinate/tegafur/uracil (UFT/LV) dosage." | 7.74 | [Two cases of recurrent colorectal cancer treated successfully with folinate/tegafur/uracil (UFT/LV) chemotherapy on an outpatient basis]. ( Hosotaki, K; Shimamoto, M; Tabira, Y; Tamori, Y, 2008) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 7.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer." | 7.72 | [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 7.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "(1) The standard chemotherapy for metastatic colorectal cancer is intravenous fluorouracil combined with calcium folinate." | 7.71 | Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages. ( , 2002) |
| "In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)." | 7.68 | [Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 7.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | 7.01 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| "Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine." | 6.94 | First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. ( Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020) |
| " In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported." | 6.82 | Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU ( Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016) |
| "8% and grade 3 or higher adverse events occurred in 12." | 6.79 | A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study. ( Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014) |
| "Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)." | 6.74 | A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009) |
| "This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)." | 6.73 | Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. ( Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007) |
| " Inactivation of DPD using eniluracil is advantageous in that it renders 5-FU orally bioavailable with more predictable pharmacokinetics and blocks one of the major potential mechanisms of 5-FU chemoresistance." | 6.71 | Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ( Diasio, RB; Heslin, MJ; Lucas, VS; Owens, J; Shao, L; Weiss, H; Yan, J, 2003) |
| "Colorectal cancer is usually diagnosed in elderly patients." | 6.71 | Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 6.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 6.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| " To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU." | 6.69 | Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999) |
| "79 patients with measurable advanced colorectal cancer (CRC) and no prior chemotherapy were included." | 6.68 | Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. ( Blanco, E; Colmenarejo, A; de la Gándara, I; Espinosa, E; Feliu, J; García-Girón, C; Garrido, P; González-Barón, M; Juárez, F; Martínez-Martínez, B, 1995) |
| "Trifluridine-tipiracil is an oral antineoplastic agent consisting of trifluridine (a trifluorothymidine, a thymidine-based nucleoside analog) and tipiracil (a thymidine phosphorylase inhibitor), at a molar ratio of 1:0." | 6.61 | The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. ( Chan, BM; Hochster, HS; Lenz, HJ, 2019) |
| "Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours." | 6.40 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999) |
| "Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC." | 5.91 | Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. ( Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023) |
| "In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer." | 5.69 | Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. ( Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2023) |
| "In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure." | 5.69 | Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study. ( Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023) |
| "Stage II colorectal cancer has a relatively good prognosis." | 5.62 | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer. ( Chen, TC; Jeng, YM; Liang, JT, 2021) |
| "Outcomes for patients with metastatic colorectal cancer (mcrc) are improving with the introduction of new treatments." | 5.51 | Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. ( Afzal, AR; Brezden-Masley, C; Cheung, WY; Dolley, A; Samawi, HH, 2019) |
| " The most common grade 3 or 4 adverse events were neutropenia (41." | 5.43 | Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. ( Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T, 2016) |
| "A literature search in the Medline/PubMed and Embase databases was executed for finding series of trifluridine/tipiracil with bevacizumab in metastatic colorectal cancer." | 5.41 | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. ( Voutsadakis, IA, 2023) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 5.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| "The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer." | 5.34 | Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ( Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A, 2020) |
| "TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer." | 5.34 | TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. ( Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D, 2020) |
| "A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile." | 5.30 | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. ( Bando, H; Horasawa, S; Kaneko, A; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Nakamura, Y; Shitara, K; Taniguchi, H; Tsuji, A; Yoshino, T, 2019) |
| "Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial." | 5.27 | Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. ( Ahn, JB; Bai, Y; Bi, F; Guo, W; Han, SW; Kim, TW; Li, J; Li, Q; Lin, D; Liu, T; Ma, D; Pan, H; Park, YS; Qin, S; Shen, L; Shi, C; Sriuranpong, V; Wu, C; Xu, J; Xu, R, 2018) |
| "In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies." | 5.27 | The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. ( Benavides, M; Ciardiello, F; Denda, T; Grávalos, C; Laurent, S; Lenz, HJ; Loehrer, P; Longo-Munoz, F; Makris, L; Mayer, RJ; Muro, K; Ohtsu, A; Portales, F; Siena, S; Tsuji, Y; Van Cutsem, E; Winkler, R; Yamaguchi, K, 2018) |
| "Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks, respectively, when compared with best supportive care alone (BSC)." | 5.27 | Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. ( Barzi, A; Cho, SK; Hay, JW, 2018) |
| "Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age." | 5.27 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. ( Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R, 2018) |
| "In patients with heavily treated metastatic colorectal cancer, TAS-102-a combination of trifluridine and tipiracil-has shown a significant overall survival benefit compared with placebo." | 5.24 | TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. ( Doi, T; Kajiwara, T; Kuboki, Y; Matsumoto, T; Mochizuki, N; Nishina, T; Nomura, S; Ohtsu, A; Okamoto, W; Sato, A; Shinozaki, E; Shitara, K; Tsushima, T; Yamazaki, K; Yoshino, T, 2017) |
| "Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC)." | 5.24 | Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. ( Antonuzzo, L; Aprile, G; Baretti, M; Battaglin, F; Berenato, R; Beretta, G; Bozzarelli, S; Cinieri, S; Cremolini, C; de Braud, F; Falcone, A; Formica, V; Ghidini, M; Lonardi, S; Loupakis, F; Marmorino, F; Mennitto, A; Miceli, R; Morano, F; Mosconi, S; Petrelli, F; Pietrantonio, F; Rimassa, L; Rossini, D; Spada, D; Tamburini, E, 2017) |
| "Oral uracil-tegafur and leucovorin (UFT/LV) therapy for elderly patients with metastatic colorectal cancer (mCRC) requires careful handling in Western countries because of a high incidence (≥20 %) of grade 3 diarrhea." | 5.20 | Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. ( Hyodo, I; Maeba, T; Matsumoto, T; Mizuta, M; Moriwaki, T; Nishina, T; Takahashi, I; Tsuji, A; Watanabe, R; Watanabe, Y, 2015) |
| "Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)." | 5.20 | Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015) |
| "Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer." | 5.20 | Randomized trial of TAS-102 for refractory metastatic colorectal cancer. ( Benedetti, F; Boucher, E; Cleary, JM; Falcone, A; Garcia-Carbonero, R; Hochster, H; Ito, M; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Mizuguchi, H; Mizunuma, N; Ohtsu, A; Peeters, M; Prenen, H; Shimada, Y; Sobrero, A; Tabernero, J; Tran, B; Van Cutsem, E; Yamazaki, K; Yoshino, T; Zaniboni, A, 2015) |
| " We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin." | 5.20 | Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ( Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T, 2015) |
| " This study investigated the impact of KRAS, NRAS, BRAF, PI3KCA and TP53 status on outcome of elderly metastatic colorectal cancer patients enrolled in TEGAFOX-E (cetuximab, oxaliplatin and oral uracil/ftorafur--UFT) phase II study." | 5.19 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. ( Bajetta, E; Beretta, E; Bertan, C; Biondani, P; Carbone, C; Di Bartolomeo, M; Dotti, KF; Lampis, A; Passalacqua, R; Perrone, F; Pietrantonio, F; Pilotti, S; Rimassa, L, 2014) |
| "To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)." | 5.19 | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014) |
| "We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer." | 5.19 | [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer]. ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2014) |
| "To identify the genes and clinical parameters associated with efficacy of uracil and tegafur/leucovorin (UFT/LV) chemotherapy in colorectal cancer (CRC), we compared the levels of reduced folate in tumors between patients receiving LV and those not receiving LV (study I), and explored the changes in the expression levels of 14 genes after two weeks of UFT/LV chemotherapy in 73 patients with CRC (study II)." | 5.17 | Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer. ( Kamijo, A; Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2013) |
| "We have reported, in a randomized, controlled study, that tegafur-uracil(UFT)and protein-bound polysaccharide K(PSK)combination therapy significantly improves the 5-year disease-free survival rate and reduces the risk of recurrence compared to UFT alone for Stage II or III colorectal cancer." | 5.17 | [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K]. ( Hirai, K; Kawate, S; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D, 2013) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 5.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 5.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 5.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "A randomized controlled trial was conducted to determine whether pathologic necrosis in response to preoperative treatment with uracil-tegafur(UFT) could be used to identify patients with colorectal cancer most likely to benefit from postoperative adjuvant therapy with the drug." | 5.13 | Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. ( Fujii, M; Kochi, M; Takayama, T, 2008) |
| "Prolonged infusions have been shown to be safer and potentially more effective than bolus regimens of 5-fluorouracil (5-FU) as treatment for metastatic colorectal cancer (mCRC)." | 5.13 | A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. ( Abbruzzese, JL; Anthony, L; Hoff, PM; Kopetz, S; Langleben, A; Lassere, Y; Rinaldi, D; Thomas, MB; Wolff, RA, 2008) |
| "To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer." | 5.13 | Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 5.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "Two phase III studies revealed an oral UFT/Leucovorin (LV) regimen, in which the drugs are taken for 28 consecutive days every 35 days, which proved to be equivalent to an infusional 5-fluorouracil/LV regimen for metastatic colorectal cancer (CRC)." | 5.12 | [Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer]. ( Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T, 2006) |
| "The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer." | 5.12 | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G, 2007) |
| "This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients." | 5.12 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| ") irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC)." | 5.12 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. ( Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D, 2007) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "Tissue samples from patients with pathologic ((p)) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU)." | 5.12 | An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Watanabe, T, 2007) |
| "To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer." | 5.12 | Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 5.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 5.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "To compare the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and leucovorin (LV) between Japanese patients and patients in the United States with previously untreated metastatic colorectal cancer." | 5.11 | Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ( Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004) |
| "The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC)." | 5.11 | Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. ( Antón-Aparicio, L; Aparicio, J; Constela, M; Dorta, FJ; Feliu, J; Fonseca, E; García-Girón, C; Gonzalez-Baron, M; Lomas, M; Vicent, JM, 2004) |
| "Although intravenous (IV) 5-fluorouracil (5-FU) and uracil/futraful (UFT) have comparable antitumour efficacy in the treatment of metastatic colorectal cancer (MCC), we wanted to assess which of these two regimens would be preferred by our patients." | 5.11 | Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. ( del Giglio, A; Lima, AP, 2005) |
| " infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC)." | 5.11 | Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. ( Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "A phase II study was performed to evaluate the clinical efficacy and toxicity of oxaliplatin combined with uracil and tegafur (UFT) in patients with advanced colorectal cancer previously treated with a fluoropyrimidine-based regimen." | 5.10 | Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. ( Chun, H; Im, YH; Jung, CW; Kang, WK; Kim, JH; Kim, K; Kim, WS; Lee, HR; Lee, JY; Lee, MH; Lee, NS; Lee, WY; Nam, E; Oh, SY; Park, CH; Park, JO; Park, K; Park, SH; Song, SY, 2002) |
| "The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or metastatic colorectal cancer." | 5.10 | A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ( Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M, 2003) |
| "Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III." | 5.10 | Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. ( Ikeya, T; Kawashima, Y; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 5.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 5.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "The purpose of this study is to evaluate the efficacy of postoperative adjuvant chemotherapy using uracil and tegafur (UFT) for colorectal cancer." | 5.10 | Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. ( Baba, S; Hasumi, A; Kato, T; Koike, A; Manabe, T; Maruta, M; Miura, K; Nakazato, H; Nimura, Y; Ohashi, Y; Saji, S; Suzuki, H; Takagi, H; Yamaguchi, A, 2002) |
| "The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer." | 5.09 | Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. ( Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001) |
| "This study was undertaken to address the influence of concurrent administration on the pharmacokinetics of UFT (uracil plus tegafur) and leucovorin (LV), and to measure the antitumor activity of a 28-consecutive-day oral regimen of UFT plus LV in patients with relapsed or refractory colorectal cancer." | 5.09 | Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. ( Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999) |
| "Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal cancer." | 5.09 | UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Díáz-Rubio, E; Fernández Martos, C; Gallén, M; Marcuello, E; Massuti, T; Navarro, M; Rifá, J; Sastre, J, 1999) |
| "Oxaliplatin is a unique platinum compound with single-agent activity in both chemotherapy-naïve colorectal cancer patients and patients who progressed on 5-fluorouracil (5-FU)." | 5.09 | Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma. ( Hoff, PM; Pazdur, R, 1999) |
| "Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) (N = 188) vs 5-fluorouracil (5-FU) plus oral calcium folinate (N = 185)." | 5.09 | Impact of uracil/tegafur plus oral calcium folinate on resource utilization. ( Ollendorf, D, 1999) |
| "This phase I trial combining UFT plus oral calcium folinate (Orzel) with irinotecan (CPT-11) (Camptosar) for the treatment of patients with advanced or metastatic colorectal cancer will open shortly." | 5.09 | UFT plus calcium folinate/irinotecan in colorectal cancer. ( Twelves, C, 1999) |
| "This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict chemosensitivity to postoperative fluoropyrimidines to prevent recurrence of disease." | 5.09 | Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. ( Fujii, M, 1999) |
| "To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)." | 5.09 | A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. ( Bonny, T; Bukowski, R; Burris, H; Hochster, H; Hohneker, J; Levin, J; Mani, S; O'Rourke, M; Schilsky, RL; Wall, JG, 2000) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 5.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "UFT (with leucovorin) and irinotecan both have single-agent activity in colorectal cancer, with non-cross-resistant mechanisms of action." | 5.09 | UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. ( Hill, M; Price, T, 2000) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 5.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "In the United States and Europe, the combination of oral UFT plus leucovorin has been reported to produce objective responses and survival rates similar to those achieved with standard intravenous 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer, with reduced toxicity." | 5.09 | UFT plus leucovorin for metastatic colorectal cancer: Japanese experience. ( Ichikawa, W; Nihei, Z; Shirota, Y; Sugihara, K; Uetake, H; Yamada, H, 2000) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 5.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 5.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 5.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "A combined phase I/II study (UFTM) of tegafururacil (UFT) and mitomycin C (MMC) was performed to find the optimal dosage for advanced colorectal cancer." | 5.08 | [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer ( Ikeda, E; Isomoto, H; Kato, T; Kodaira, S; Okuda, M; Takahashi, T; Teramoto, T; Yamamoto, Y, 1996) |
| "The activity and toxicity of UFT (Tegafur and Uracil) in a 4:1 molar concentration, plus leucovorin (LV), were evaluated in the treatment of 45 patients with advanced, bidimensionally measurable metastatic colorectal carcinoma." | 5.08 | Phase II study of UFT plus leucovorin in colorectal cancer. ( Pazdur, R, 1997) |
| "A phase II trial of UFT (Tegafur and Uracil) modulated by leucovorin was undertaken by the Oncopaz Cooperative Group to assess the efficacy and toxicity of this combination in patients with advanced colorectal cancer." | 5.08 | UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. ( Blanco, E; Colmenarejo, A; Crespo, MC; de Castro, J; Espinosa, E; Espinosa, J; Feliu, J; Garcia Girón, C; González Barón, M; Juárez, F; Martinez, B; Ordóñez, A, 1997) |
| "Therapeutic options for patients with advanced colorectal cancer who have failed treatment with fluorouracil (5-FU) are limited." | 5.08 | Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. ( Birkhofer, MJ; Meropol, NJ; Noel, D; Sonnichsen, DS, 1997) |
| "Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking." | 5.05 | Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? ( Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q, 2020) |
| "Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)." | 5.01 | A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. ( Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019) |
| "Regorafenib and TAS-102 have shown to be superior to placebo in refractory metastatic colorectal cancer." | 4.98 | A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. ( Abrahao, ABK; Berry, S; Chan, KKW; Ko, YJ, 2018) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "5-Fluorouracil (5-FU) has been the most widely used chemotherapeutic agent for metastatic colorectal cancer (mCRC) and 5-FU combination therapy improves efficacy compared with monotherapy." | 4.85 | The role of UFT in metastatic colorectal cancer. ( Bennouna, J; Douillard, JY; Saunders, M, 2009) |
| "In Western countries, efficacy of 5-fluorouracil (5-FU)+leucovorin (LV) as adjuvant chemotherapy for colorectal cancer has been already established." | 4.83 | [Adjuvant chemotherapy for colorectal cancer]. ( Akasu, T, 2006) |
| "Since its synthesis over 40 years ago, several studies including patients with colorectal cancer have shown that prolonged exposure to 5-fluorouracil (5-FU) is associated with better antitumor activity and decreased toxicity." | 4.82 | Practical considerations in the use of oral fluoropyrimidines. ( Hoff, PM, 2003) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 4.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "5-fluorouracil (5-FU) plus leucovorin (LV) therapy is the most widely used regimen with a high evidence as the first-line treatment for advanced colorectal cancer (CRC), as well as CPT-11 as the second-line." | 4.82 | [Chemotherapy for colorectal carcinoma]. ( Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H, 2003) |
| " Oral prodrugs of 5-FU, such as capecitabine and uracil, have been developed in order to mimic the protracted infusion schedule of 5-FU, and these drugs may change the daily practice of palliative chemotherapy for colorectal cancer in the coming years." | 4.82 | New developments in systemic chemotherapy in advanced colorectal cancer. ( Cats, A, 2003) |
| "5-Fluorouracil (5-FU) administered in several schedules since its introduction in 1957 continues to be an integral part of standard first-line therapy for colorectal cancer." | 4.82 | The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. ( Beretta, GD; Labianca, R; Milesi, L; Mosconi, S, 2004) |
| "In colorectal cancer, leucovorin-modulated 5-fluorouracil (5-FU) has been the mainstay of both adjuvant treatment and treatment of metastatic disease for many years." | 4.81 | Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. ( Cunningham, D; James, RD, 2001) |
| "For several decades fluoropyrimidines, especially 5-fluorouracil (5-FU), have played a role in standard chemotherapy regimens for a range of solid tumours, including breast and colorectal cancers." | 4.81 | New options for outpatient chemotherapy--the role of oral fluoropyrimidines. ( Coleman, R; Cunningham, D, 2001) |
| "5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since its initial development 40 years ago." | 4.80 | Oral fluoropyrimidines in the treatment of colorectal cancer. ( Meropol, NJ, 1998) |
| "After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer." | 4.80 | Fluoropyrimidines: a critical evaluation. ( Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH, 1999) |
| "For years, 5-fluorouracil (5-FU) was the only chemotherapeutic agent for the treatment of patients with advanced colorectal cancer." | 4.80 | New drugs in therapy of colorectal cancer: preclinical studies. ( Cao, S; Rustum, YM, 1999) |
| "Protracted intravenous infusions of fluorouracil (5-FU) in the treatment of colorectal cancer have been associated with a reduction in toxicity and enhanced clinical activity compared with bolus 5-FU schedules." | 4.80 | Oral fluoropoyrimidines. ( Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M, 1999) |
| "The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade." | 4.80 | The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. ( Papamichael, D, 1999) |
| " This review describes several oral fluoropyrimidine regimens with activity in colorectal cancer: capecitabine (Xeloda), tegafur, UFT, S-1, and eniluracil plus 5-FU." | 4.80 | Oral therapy for colorectal cancer: how to choose. ( Damjanov, N; Meropol, NJ, 2000) |
| "For several years, fluorinated pyrimidines have been used in the treatment of advanced colorectal cancer, mainly in the form of intravenous injections of 5-fluorouracil (5-FU), alone or in combination with leucovorin." | 4.80 | [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer]. ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000) |
| "Fluorouracil (5-FU) has remained the standard therapy for the treatment of advanced colorectal cancer for over 40 years." | 4.80 | Colorectal cancer: chemotherapy treatment overview. ( Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH, 2000) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer." | 4.31 | An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. ( Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023) |
| "Trifluridine/tipiracil and regorafenib are indicated for metastatic colorectal cancer (mCRC) patients' refractory to standard chemotherapy." | 4.31 | TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. ( Antista, M; Antoniotti, C; Boccaccino, A; Borelli, B; Conca, V; Cremolini, C; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Germani, MM; Leone, AG; Marmorino, F; Masi, G; Moretto, R; Pietrantonio, F; Provenzano, L; Rossini, D; Spagnoletti, A, 2023) |
| "Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC)." | 4.31 | Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. ( Ikoma, T; Matsumoto, T; Miura, K; Nagai, H; Takatani, M; Tsuduki, T; Watanabe, T; Yamamura, S; Yasui, H, 2023) |
| "Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the United States for treatment of refractory metastatic colorectal cancer (mCRC)." | 4.31 | A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. ( Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J, 2023) |
| "We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage." | 4.31 | A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023) |
| "Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting." | 4.31 | Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. ( Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D, 2023) |
| "The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial." | 4.31 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. ( Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023) |
| "In the pivotal RECOURSE trial, trifluridine/tipiracil improved survival outcomes in refractory metastatic colorectal cancer (mCRC), while demonstrating an acceptable toxicity profile." | 4.31 | The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. ( Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR, 2023) |
| "Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC)." | 4.31 | Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ( Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T, 2023) |
| "Trifluridine/tipiracil (TAS-102) is an anticancer drug for metastatic colorectal cancer (CRC)." | 4.31 | Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study. ( Doi, T; Ikeda, J; Ishikawa, T; Itoh, Y; Kirishima, T; Kudou, M; Kuriu, Y; Miyagawa, K; Nakanishi, M; Okayama, T; Otsuji, E; Takagi, T; Yoshida, N, 2023) |
| "This study suggests that tegafur/uracil plus leucovorin is a feasible adjuvant chemotherapy regimen for patients with stage II colorectal cancer after curative surgical treatment." | 4.31 | Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan. ( Chen, HH; Fan, CW; Liao, CK; Liaw, YW; Liu, YH; Tseng, WK; Yeh, CY; Yu, YL, 2023) |
| "Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102)." | 4.31 | Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. ( Fujii, H; Hirose, C; Hishida, S; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Suzuki, A; Tajima, JY; Takahashi, T; Watanabe, D, 2023) |
| "For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 4.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 4.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 4.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 4.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
| "The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited." | 4.12 | Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. ( Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022) |
| "Combination therapy of tegafur/uracil (UFT) and leucovorin (LV) is widely used to treat colorectal cancers." | 4.02 | Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. ( Endo, Y; Hirashita, T; Inomata, M; Itoh, H; Iwao, M; Iwashita, Y; Masuda, T; Shiraiwa, K; Suzuki, Y; Tada, K; Tanaka, R; Uchida, H, 2021) |
| "Trifluridine/tipiracil (TAS-102) is an important chemotherapeutic agent recommended by the Japanese guidelines as third- or fourth-line treatment for colorectal cancer." | 4.02 | [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab]. ( Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021) |
| "Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes." | 3.96 | Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. ( Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Hatachi, Y; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Oki, E; Sakai, D; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Tsuchihashi, K; Tsuji, A; Ueno, H; Yamashita, K; Yamazaki, K, 2020) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 3.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents." | 3.96 | Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. ( Burge, M; Chantrill, L; Gibbs, P; Pavlakis, N; Price, T; Shapiro, J; Sjoquist, K, 2020) |
| "Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments." | 3.96 | Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. ( Hatachi, Y; Kato, T; Kotaka, M; Ogata, M; Ogata, T; Satake, H; Tsuji, A; Yasui, H, 2020) |
| "The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated." | 3.96 | Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. ( Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Maeda, K; Nagahara, H; Ohira, M; Okazaki, Y; Shibutani, M; Wang, EN, 2020) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 3.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear." | 3.91 | Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ( Kadowaki, S; Kawakami, T; Kawamoto, Y; Komatsu, Y; Masuishi, T; Muranaka, T; Muro, K; Nakatsumi, H; Omae, K; Onozawa, Y; Tajika, M; Taniguchi, H; Yamazaki, K; Yasui, H; Yuki, S, 2019) |
| "Regorafenib and TAS-102 are standard salvage-line treatment options for patients with chemorefractory metastatic colorectal cancer (mCRC)." | 3.91 | Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer. ( Akiyama, T; Baba, H; Baba, Y; Eto, K; Hiyoshi, Y; Iwagami, S; Kiyozumi, Y; Miyamoto, Y; Yohei, N; Yoshida, N, 2019) |
| "Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer." | 3.91 | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance." | 3.91 | ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019) |
| "The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS)." | 3.91 | The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. ( Bonetti, A; Giuliani, J, 2019) |
| "This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment." | 3.88 | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. ( Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K, 2018) |
| " Clinical data were derived from the pivotal phase III (Randomized, Double-Blind, Phase 3 Study of TAS-102 plus Best Supportive Care [BSC] versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapies [RECOURSE]) and supporting phase II (J003-10040030) randomized controlled trial of trifluridine/tipiracil + BSC versus placebo + BSC, as well as the phase III Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (CORRECT) randomized controlled trial of regorafenib, and were extrapolated to estimate lifetime outcomes." | 3.88 | Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. ( Bullement, A; Fougeray, R; Hatswell, AJ; Underhill, S, 2018) |
| "Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor), led to significant improvement in overall survival in metastatic colorectal cancer (mCRC) patients refractory to standard therapy in the phase III RECOURSE trial." | 3.88 | Integrated safety summary for trifluridine/tipiracil (TAS-102). ( Bebeau, P; Bendell, JC; Buscaglia, M; Falcone, A; Kopetz, S; Mayer, RJ; Ohtsu, A; Van Cutsem, E; Yoshino, T, 2018) |
| "The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients." | 3.88 | Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018) |
| "Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 3.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
| "A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared." | 3.88 | Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. ( Baba, E; Denda, T; Esaki, T; Fukuoka, S; Ishikawa, T; Ito, M; Kajiwara, T; Kashiwada, T; Katsumata, K; Kishimoto, J; Komatsu, Y; Kumekawa, Y; Makiyama, A; Moriwaki, T; Oki, E; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Tsuchihashi, K; Ueno, H; Yamashita, K; Yamazaki, K, 2018) |
| "Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI) inhibits the rapid degradation of FTD." | 3.85 | Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. ( Barzi, A; Berger, MD; Borelli, B; Cao, S; Dadduzio, V; Gopez, R; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Pietrantonio, F; Salvatore, L; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W, 2017) |
| "Trifluridine/tipiracil (TFTD, TAS-102) is an orally administrated anti-cancer drug with efficacy validated for patients with metastatic colorectal cancer (mCRC)." | 3.85 | Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. ( Iimori, M; Kiniwa, M; Kitao, H; Kurashige, J; Maehara, Y; Morodomi, Y; Nakanishi, R; Nakashima, Y; Oki, E; Saeki, H; Sugiyama, M, 2017) |
| "The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated." | 3.85 | Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017) |
| "We assessed the role of aspirin in patients with metastatic colorectal cancer who failed all previous treatments and were receiving capecitabine as a salvage option before the introduction of regorafenib and TAS-102." | 3.85 | The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. ( Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L, 2017) |
| "Regorafenib and trifluridine/tipiracil (TAS-102) both prolong survival for patients with refractory metastatic colorectal cancer." | 3.85 | Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. ( Ando, M; Fukutomi, A; Hamauchi, S; Ishihara, M; Kadowaki, S; Kito, Y; Komori, A; Machida, N; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Tajika, M; Tanaka, T; Taniguchi, H; Todaka, A; Tsushima, T; Ura, T; Yamazaki, K; Yasui, H; Yokota, T, 2017) |
| "This study sought to compare UFT/LV with capecitabine as adjuvant chemotherapy for the treatment of stage III colorectal cancer." | 3.83 | [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer]. ( Maruyama, T; Okumura, M; Sako, A; Ueda, K; Yasuda, K, 2016) |
| "Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine." | 3.83 | TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape? ( Barni, S; Bertocchi, P; Petrelli, F; Zaniboni, A, 2016) |
| "TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC)." | 3.83 | Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. ( Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T, 2016) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 3.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "TAS-102, which is effective for refractory metastatic colorectal cancer, is a combination drug of anticancer trifluridine (FTD; which is derived from pyrimidine nucleoside) and FTD-metabolizing enzyme inhibitor tipiracil hydrochloride (TPI) at a molecular ratio of 1:0." | 3.81 | Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells. ( Chiba, M; Nakanishi, T; Takahashi, K; Tamai, I; Yoshisue, K, 2015) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)." | 3.79 | Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)." | 3.79 | Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated." | 3.79 | A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "To identify useful predictive factors for the response to 5-fluorouracil (5-FU)/leucovorin (LV) and oral uracil and tegafur (UFT)/LV chemotherapy among patients with colorectal cancer, we investigated the association between the gene expression levels of pyrimidine and folate metabolism-related enzymes in colorectal cancer (CRC) tissues and the response to UFT/LV neoadjuvant chemotherapy." | 3.78 | Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. ( Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2012) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 3.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "Quality of life (QOL) was measured prospectively using the European Organization for Research and Treatment of Cancer QLQ-C30 (QLQ-C30) and Functional Assessment of Cancer Therapy-General (FACT-G) in 94 colorectal cancer patients who received adjuvant chemotherapy with oral uracil/tegafur plus leucovorin." | 3.76 | [European Organization for Research and Treatment of Cancer QLQ-C30 and functional assessment of cancer therapy- general for measurement of quality of life in colorectal cancer patients who received adjuvant chemotherapy- a comparison]. ( Tsunoda, A, 2010) |
| "To establish the sufficient therapy for elderly colorectal cancer patients, we retrospectively compared postoperative Tegafur/Uracil (UFT; Taiho Pharmaceutical Co." | 3.75 | Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. ( Takashima, S; Yoshitani, S, 2009) |
| " This study was conducted to examine changes in DPD activity in peripheral mononuclear cells (PMNC) during long-term treatment with oral uracil and tegafur (UFT) for colorectal cancer." | 3.74 | Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. ( Ishikawa, K; Kamijo, A; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2007) |
| "We report two cases of recurrent colorectal cancer in two patients who were treated successfully with a combined oral chemotherapeutic agent folinate/tegafur/uracil (UFT/LV) dosage." | 3.74 | [Two cases of recurrent colorectal cancer treated successfully with folinate/tegafur/uracil (UFT/LV) chemotherapy on an outpatient basis]. ( Hosotaki, K; Shimamoto, M; Tabira, Y; Tamori, Y, 2008) |
| "To evaluate ambulatory patient cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 19 patients with non-curative or recurrent colorectal cancer who were treated by Uracil/Tegafur (UFT) plus oral Leucovorin (UZEL) for the past 2 years." | 3.73 | [Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer]. ( Fujiwara, H; Hamabe, Y; Ishida, T; Kaji, M; Mukai, H; Mukubou, H; Onishi, N; Sato, S; Toyokawa, A; Tsujimura, T; Tsukamoto, T; Wakahara, T; Wakita, K; Watanabe, A, 2005) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 3.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| "The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer." | 3.72 | [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 3.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "(1) The standard chemotherapy for metastatic colorectal cancer is intravenous fluorouracil combined with calcium folinate." | 3.71 | Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages. ( , 2002) |
| "This study was designed to examine the optimal regimen of 5-fluorouracil (5-FU), uracil and degradable starch microspheres (DSM) to prevent the hepatic metastasis of colorectal cancer." | 3.69 | Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer. ( Fujii, K; Hanaue, H; Kurosawa, T; Mitomi, T; Nakasaki, H; Tajima, T; Yasuda, S, 1994) |
| " A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats." | 3.69 | Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997) |
| "In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)." | 3.68 | [Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 3.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| "A phase II trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with advanced gastric cancer." | 3.68 | Phase II trial of UFT in advanced colorectal and gastric cancer. ( Clarke, PI; Malik, ST; Osborne, R; Reznek, R; Slevin, ML; Talbot, D; Wrigley, PF, 1990) |
| "The concentration of Tegafur, 5-FU and Uracil in tumor and normal tissue were measured in 47 colorectal cancer patients who had been administered UFT (400/mg) for seven days before operation." | 3.67 | [Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration]. ( Eida, K; Fukuda, Y; Hirano, T; Ishii, T; Kotake, Y; Kusano, H; Nakagoe, T; Shimizu, T; Shimoyama, T; Tomita, M, 1988) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | 3.01 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| "Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine." | 2.94 | First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. ( Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020) |
| "The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate." | 2.87 | MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. ( Alabiso, I; Alabiso, O; Baratelli, C; Brizzi, MP; Di Maio, M; Forti, L; Ottone, A; Scagliotti, GV; Sonetto, C; Tampellini, M, 2018) |
| " The overall incidence of any Grade adverse events (AEs) were 91." | 2.87 | Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. ( Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K, 2018) |
| " In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported." | 2.82 | Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU ( Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016) |
| "8% and grade 3 or higher adverse events occurred in 12." | 2.79 | A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study. ( Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014) |
| "We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer." | 2.78 | [Treatment outcome of peptide vaccination for advanced colorectal cancer]. ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2013) |
| "Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)." | 2.74 | A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009) |
| " In this single-dose, randomized, two-way crossover study, we investigated the effects of a low-fat Japanese meal on the pharmacokinetics and oral bioavailability of UFT (2 x 100-mg capsules; dose in terms of tegafur) and leucovorin (1 x 25-mg tablet)." | 2.74 | Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer. ( Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009) |
| "This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)." | 2.73 | Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. ( Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007) |
| "Twenty-two patients with metastatic colorectal cancer were enrolled in the phase I trial and 35 patients (including eight patients treated at level 4 during phase I) were evaluated in the phase II trial." | 2.73 | Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. ( Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N, 2007) |
| " Inactivation of DPD using eniluracil is advantageous in that it renders 5-FU orally bioavailable with more predictable pharmacokinetics and blocks one of the major potential mechanisms of 5-FU chemoresistance." | 2.71 | Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ( Diasio, RB; Heslin, MJ; Lucas, VS; Owens, J; Shao, L; Weiss, H; Yan, J, 2003) |
| "In addition, remote metastases tended to be suppressed for both colon and rectal cancer in Group A (p=0." | 2.71 | Pre- and post-operative adjuvant chemotherapy in colorectal cancer. ( Isomoto, H; Kakegawa, T; Mori, M; Nakagoe, T; Ogawa, M; Sugimachi, K; Takano, S; Tomita, M; Yamada, K, 2003) |
| "Colorectal cancer is usually diagnosed in elderly patients." | 2.71 | Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 2.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| " The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study." | 2.70 | Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. ( Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 2.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "Twenty-two colorectal cancer patients (infusion group) in Dukes' C stage were given hepatic arterial infusion of 5-FU (500 mg/body for 1 hr per week, repeated 50 times) and peroral UFT-E (2." | 2.69 | [Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer]. ( Fujioka, M; Idezuki, Y; Inokuma, S; Ishida, H; Kamano, T; Kishi, T; Kondo, K; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Shimomura, K; Suzuki, T; Takeuchi, I; Yamada, H, 1999) |
| " To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU." | 2.69 | Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999) |
| "Treatment with eniluracil will eliminate DPD activity as a source of pharmacokinetic fluorouracil variability or resistance in human colorectal cancer." | 2.69 | Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. ( Abeling, NG; Ahmed, FY; Binnie, N; Cassidy, J; Johnston, SJ; Knight, S; McLeod, HL; Murray, GI; O'Kelly, T; van Gennip, AH, 1999) |
| " Four patients who suffered from PMC-related side effects of grade 1-2 wanted to decrease their dosage of UFT and/or 5-FU." | 2.69 | [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report]. ( Izumi, S; Nakagawa, J; Nishihara, M; Onoda, Y; Shimizu, N; Shiota, K; Suzuka, I, 1999) |
| "Twenty cases of advanced colorectal cancer were entered into the study." | 2.69 | Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study. ( Laohavinij, S; Maoleekoonpairoj, S; Thavichaigarn, P; Thongprasert, S, 2000) |
| "Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT." | 2.69 | Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000) |
| " We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer." | 2.69 | UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca. ( Jakobsen, A, 2000) |
| "79 patients with measurable advanced colorectal cancer (CRC) and no prior chemotherapy were included." | 2.68 | Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. ( Blanco, E; Colmenarejo, A; de la Gándara, I; Espinosa, E; Feliu, J; García-Girón, C; Garrido, P; González-Barón, M; Juárez, F; Martínez-Martínez, B, 1995) |
| "The subjects were 39 patients with gastric cancer and 44 patients with colorectal cancer divided into a group administered 400 mg/day of UFT orally for 2 weeks preoperatively (UFT group) and a group administered 400 mg/day of UFT as well as 40 mg/m2 (i." | 2.68 | [Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat]. ( Fuchino, Y; Ikeda, S; Kimura, H; Mitsuishi, K; Tanaka, S; Tomita, A; Umeno, T, 1997) |
| "Trifluridine-tipiracil is an oral antineoplastic agent consisting of trifluridine (a trifluorothymidine, a thymidine-based nucleoside analog) and tipiracil (a thymidine phosphorylase inhibitor), at a molar ratio of 1:0." | 2.61 | The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. ( Chan, BM; Hochster, HS; Lenz, HJ, 2019) |
| "Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed." | 2.55 | Oral versus intravenous fluoropyrimidines for colorectal cancer. ( Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y, 2017) |
| "Molecular mechanisms of colorectal cancer are at the forefront of research." | 2.53 | Current and advancing treatments for metastatic colorectal cancer. ( Argiles, G; Elez, ME; Grasselli, J; Sanz-Garcia, E; Tabernero, J, 2016) |
| " The rapid degradation of TFT brought initial clinical development to a halt, but TFT reentered clinical trials when addition of a TPI was found to improve the bioavailability of TFT." | 2.53 | TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. ( Opdam, FL; van der Velden, DL; Voest, EE, 2016) |
| "Chemotherapy for advanced colorectal cancer is much improved in this decade." | 2.43 | [Second-line chemotherapy for advanced colorectal cancer]. ( Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M, 2005) |
| "A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago." | 2.43 | Chemotherapy for colorectal cancer. ( Goyle, S; Maraveyas, A, 2005) |
| "In stage II colon cancer, treatment strategies are more debated." | 2.43 | [Adjuvant treatment of colorectal cancer]. ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006) |
| "Metastatic colorectal cancer remains a public-health issue on a global scale." | 2.43 | Metastatic colorectal cancer. ( Cavalli, F; Saletti, P, 2006) |
| "Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures." | 2.42 | Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003) |
| "New targets in the treatment of colorectal cancer are the EGF and VEGF receptor." | 2.42 | The role of new agents in the treatment of colorectal cancer. ( Folprecht, G; Köhne, CH, 2004) |
| "Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice." | 2.41 | [Progress in adjuvant therapy for colorectal cancer]. ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002) |
| " Phase I studies have been completed showing the tolerability of two dosing schedules, including (1) a chronic schedule with twice-daily administration of eniluracil plus oral fluorouracil (5-FU) (10:1 ratio) for 28 days, and (2) a schedule of eniluracil administered daily on days 1-7 with oral 5-FU once daily on days 2-6." | 2.41 | Oral eniluracil/5-FU for advanced colon and breast carcinomas. ( Benson, AB, 2001) |
| "Treatment for advanced colorectal cancer has nevertheless made progress in the last few years." | 2.41 | New drugs and combinations in the palliative treatment of colon and rectal cancer. ( Beretta, GD; Labianca, R; Mosconi, S; Pessi, MA; Poletti, P, 2001) |
| "Metastatic colorectal cancer has traditionally been treated with i." | 2.41 | Answering patients' needs: oral alternatives to intravenous therapy. ( Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H, 2001) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| "Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (DPD), which is the first enzyme in the degradative pathway of systemically administered 5-fluorouracil (5-FU)." | 2.40 | Clinical development of eniluracil: current status. ( Hohneker, JA, 1998) |
| "Tegafur acts as a prodrug of 5-fluorouracil (5-FU), being slowly metabolized by cytochrome P450 to 5-FU." | 2.40 | UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ( Benner, SE; Canetta, R; Hoff, PM; Pazdur, R, 1998) |
| "5-fluorouracil has been the major chemotherapeutic agent for the treatment of colorectal carcinoma for the past four decades." | 2.40 | A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. ( Adjei, AA, 1999) |
| "Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours." | 2.40 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999) |
| " Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation." | 2.39 | Preclinical and clinical aspects of biomodulation of 5-fluorouracil. ( Allegra, CJ; Grogan, L; Sotos, GA, 1994) |
| "Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC." | 1.91 | Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. ( Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023) |
| " No unexpected adverse events were observed in both groups." | 1.91 | Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. ( Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K, 2023) |
| "Regorafenib was the treatment for 22." | 1.72 | Regorafenib and trifluridine/tipiracil in real clinical practice. ( de Castro, NM; García-Beloso, N; Gayoso-Rey, M; López-López, A; Piñeiro-Corrales, G; Robles-Torres, D; Romero-Ventosa, EY, 2022) |
| "Stage II colorectal cancer has a relatively good prognosis." | 1.62 | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer. ( Chen, TC; Jeng, YM; Liang, JT, 2021) |
| "Trifluridine/tipiracil was more cost-effective than nivolumab for patients with heavily pretreated metastatic gastric cancer." | 1.62 | Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. ( Doi, T; Igarashi, A; Shitara, K; Takushima, Y; Yoshihara, H, 2021) |
| "Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ) is an aggressive disease with poor prognosis." | 1.62 | Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ( Alsina, M; Arkenau, HT; Azcue, P; Catenacci, DVT; Doi, T; Fornaro, L; Fougeray, R; Ilson, DH; Lorenzen, S; Moreno, SR; Shitara, K; Tabernero, J; Van Cutsem, E; Zaanan, A, 2021) |
| "Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC refractory to standard therapies." | 1.56 | Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. ( Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020) |
| "Outcomes for patients with metastatic colorectal cancer (mcrc) are improving with the introduction of new treatments." | 1.51 | Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. ( Afzal, AR; Brezden-Masley, C; Cheung, WY; Dolley, A; Samawi, HH, 2019) |
| "Neutropenia is the most common adverse event and an important factor impacting chemotherapy continuation." | 1.48 | Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. ( Aisu, N; Daibo, K; Hasegawa, S; Kajitani, R; Kiyomi, F; Komono, A; Matsumoto, Y; Munechika, T; Sakamoto, R; Yoshida, Y, 2018) |
| " The most common grade 3 or 4 adverse events were neutropenia (41." | 1.43 | Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. ( Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T, 2016) |
| " The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%)." | 1.43 | Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer. ( Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Kusaba, H; Makiyama, A; Matsushita, Y; Mitsugi, K; Shibata, Y; Shimokawa, HK; Shirakawa, T; Tamura, S, 2016) |
| " This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs) of TAS-102 in clinical practice in the first 6 months after market launch." | 1.43 | TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. ( Fujita, N; Furuta, T; Hara, N; Katori, J; Muro, K; Uetake, H; Yoshino, T, 2016) |
| "Here, we present the first case of interstitial lung disease occurring in association with TAS-102 treatment." | 1.43 | Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report. ( Akagi, Y; Ishibashi, N; Kamei, H; Tanigawa, M; Uchida, M; Yamaguchi, K, 2016) |
| "In the present study, we used colorectal cancer xenografts to assess whether the efficacy of TAS-102 could be improved by combining it with bevacizumab, cetuximab or panitumumab." | 1.42 | Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. ( Ishida, K; Matsuo, K; Nakagawa, F; Okabe, H; Sakamoto, K; Takechi, T; Tanaka, N; Tsukihara, H; Uchida, J, 2015) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 1.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| "98 gastric and 135 colorectal cancer patients were analyzed." | 1.39 | Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). ( Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Mimori, K; Morita, M; Oki, E; Saeki, H; Soejima, Y; Sugimachi, K; Uchiyama, H; Watanabe, M; Yamashita, Y; Yoshinaga, K; Yoshizumi, T, 2013) |
| " Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy." | 1.39 | LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. ( Amstutz, U; Büchel, B; Bühr, C; Largiadèr, CR; Rhyn, P; Schürch, S, 2013) |
| "Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly catabolizes 5-fluorouracil (5-FU)." | 1.36 | A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil. ( Cao, S; Spector, T, 2010) |
| "HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups." | 1.36 | Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study." | 1.35 | Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. ( Hattori, T; Itoh, K; Komatsu, N; Mine, T; Okuno, K; Shiozaki, H; Yamada, A, 2009) |
| "In advanced colorectal cancer (ACC), FOLFOX4 has been accepted as a standard chemotherapeutic regimen." | 1.34 | UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. ( Brugnatelli, S; Corazza, GR; Gattoni, E; Luchena, G; Riccardi, A; Sagrada, P; Scalamogna, R; Tinelli, C; Tronconi, MC, 2007) |
| " A dosage of 335 mg/m2/day of UFT was given perorally on daily schedule." | 1.34 | Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence. ( Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M, 2007) |
| "The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed." | 1.33 | The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006) |
| "Pretreatment with eniluracil (5-ethynyluracil) prevents catabolism of FU." | 1.31 | Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. ( Alauddin, MM; Bading, JR; Conti, PS; Fissekis, JD; Joung, J; Shahinian, AH; Spector, T, 2000) |
| "The subjects were 24 colorectal cancer patients." | 1.31 | A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. ( Iwase, H; Kameya, T; Makuuchi, H; Sadahiro, S; Suzuki, T; Tajima, T, 2001) |
| "We measured the chemosensitivity of colorectal cancer to 5-FU by MTT assay using specimens from colonoscopy, and compared this with the histopathological effects." | 1.30 | [Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer]. ( Fujii, M; Imai, S; Mochizuki, F, 1999) |
| " A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86." | 1.30 | [UFT-E granule compliance in postoperative adjuvant chemotherapy]. ( Hagiwara, M; Hanai, A; Kanasugi, K; Komoriyama, H; Yamaguchi, S, 1999) |
| " Rats were dosed p." | 1.29 | 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995) |
| "Evaluability of gastric and breast cancers was very low because of the poor growth of the grafts irrespective of the immunity of host animals." | 1.29 | [Evaluation of subrenal capsule assay (SRC) for clinical cancers]. ( Akao, S; Ishikawa, H; Iwami, N; Kiumi, F; Oya, M; Sasaki, K; Terada, H, 1996) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.72) | 18.7374 |
| 1990's | 68 (16.39) | 18.2507 |
| 2000's | 150 (36.14) | 29.6817 |
| 2010's | 132 (31.81) | 24.3611 |
| 2020's | 62 (14.94) | 2.80 |
| Authors | Studies |
|---|---|
| Jalali, A | 1 |
| Gard, G | 1 |
| Banks, S | 1 |
| Dunn, C | 1 |
| Wong, HL | 1 |
| Wong, R | 1 |
| Lee, M | 1 |
| Gately, L | 1 |
| Loft, M | 1 |
| Shapiro, JD | 1 |
| Kosmider, S | 1 |
| Tie, J | 1 |
| Ananda, S | 1 |
| Yeung, JM | 1 |
| Jennens, R | 1 |
| Lee, B | 1 |
| McKendrick, J | 1 |
| Lim, L | 1 |
| Khattak, A | 1 |
| Gibbs, P | 2 |
| Stavraka, C | 1 |
| Pouptsis, A | 1 |
| Synowiec, A | 1 |
| Angelis, V | 1 |
| Satterthwaite, L | 1 |
| Khan, S | 1 |
| Chauhan, M | 1 |
| Holden, C | 1 |
| Young, S | 1 |
| Karampera, C | 1 |
| Martinou, M | 1 |
| Mills-Baldock, T | 1 |
| Baxter, M | 1 |
| Barry, A | 1 |
| Eccles, B | 1 |
| Iveson, T | 2 |
| Shiu, KK | 2 |
| Hill, M | 3 |
| Abdel-Raouf, S | 1 |
| Graham, JS | 1 |
| Thomas, A | 1 |
| Ross, PJ | 2 |
| Talaat, W | 1 |
| Kaddah, MMY | 1 |
| Keshk, RM | 1 |
| Giuliani, J | 3 |
| Sousa, MJ | 1 |
| Gomes, I | 1 |
| Pereira, TC | 1 |
| Magalhães, J | 1 |
| Basto, R | 1 |
| Paulo, J | 1 |
| Jacinto, P | 1 |
| Bonito, N | 1 |
| Sousa, G | 1 |
| Coutzac, C | 1 |
| Trouilloud, I | 1 |
| Artru, P | 2 |
| Henriques, J | 1 |
| Masson, T | 1 |
| Doat, S | 1 |
| Bouché, O | 1 |
| Coriat, R | 1 |
| Saint, A | 1 |
| Moulin, V | 1 |
| Vernerey, D | 1 |
| Gallois, C | 1 |
| De La Fouchardière, C | 1 |
| Tougeron, D | 1 |
| Taieb, J | 3 |
| Oshima, K | 1 |
| Hirano, H | 1 |
| Shoji, H | 1 |
| Iwasa, S | 1 |
| Okita, N | 1 |
| Takashima, A | 5 |
| Boku, N | 4 |
| Yoshino, T | 16 |
| Van Cutsem, E | 13 |
| Li, J | 5 |
| Shen, L | 3 |
| Kim, TW | 2 |
| Sriuranpong, V | 2 |
| Xuereb, L | 1 |
| Aubel, P | 1 |
| Fougeray, R | 4 |
| Cattan, V | 1 |
| Amellal, N | 2 |
| Ohtsu, A | 17 |
| Mayer, RJ | 8 |
| Martínez-Lago, N | 1 |
| Chucla, TC | 1 |
| De Castro, BA | 1 |
| Ponte, RV | 1 |
| Rendo, CR | 1 |
| Rodriguez, MIG | 1 |
| Diaz, SS | 1 |
| Suarez, BG | 1 |
| de la Cámara Gomez, J | 2 |
| Fernández, FB | 1 |
| Salvador, MM | 1 |
| Lopez, MR | 1 |
| Arrichiello, G | 1 |
| Perrone, A | 1 |
| Napolitano, S | 2 |
| Martini, G | 3 |
| De Falco, V | 2 |
| Incoronato, P | 1 |
| Laterza, MM | 1 |
| Facchini, G | 1 |
| Famiglietti, V | 2 |
| Nacca, V | 1 |
| Paragliola, F | 1 |
| Napolitano, R | 1 |
| Suarato, G | 1 |
| Nicastro, A | 1 |
| Martinelli, E | 3 |
| Ciardiello, D | 2 |
| Ciardiello, F | 5 |
| Troiani, T | 3 |
| Hochster, H | 7 |
| Shitara, K | 11 |
| Mayer, R | 3 |
| Falcone, A | 10 |
| Doi, T | 12 |
| Ilson, DH | 4 |
| Arkenau, HT | 4 |
| George, B | 3 |
| Benhadji, KA | 5 |
| Makris, L | 8 |
| Tabernero, J | 10 |
| García-Beloso, N | 2 |
| Romero-Ventosa, EY | 2 |
| Gayoso-Rey, M | 2 |
| López-López, A | 2 |
| Robles-Torres, D | 2 |
| de Castro, NM | 2 |
| Piñeiro-Corrales, G | 2 |
| Fidelman, N | 2 |
| Atreya, CE | 2 |
| Griffith, M | 2 |
| Milloy, MA | 2 |
| Carnevale, J | 2 |
| Cinar, P | 2 |
| Venook, AP | 2 |
| Van Loon, K | 2 |
| Nie, C | 1 |
| Xu, W | 1 |
| Chen, B | 1 |
| Lv, H | 1 |
| Wang, J | 2 |
| Liu, Y | 1 |
| He, Y | 1 |
| Wang, S | 1 |
| Zhao, J | 1 |
| Chen, X | 1 |
| Borelli, B | 3 |
| Crucitta, S | 1 |
| Boccaccino, A | 1 |
| Antista, M | 1 |
| Antoniotti, C | 3 |
| Marmorino, F | 4 |
| Rossini, D | 5 |
| Conca, V | 1 |
| Germani, MM | 1 |
| Provenzano, L | 1 |
| Spagnoletti, A | 1 |
| Leone, AG | 1 |
| Cucchiara, F | 1 |
| Pietrantonio, F | 5 |
| Del Re, M | 1 |
| Danesi, R | 1 |
| Masi, G | 3 |
| Cremolini, C | 5 |
| Moretto, R | 2 |
| Ding, PQ | 1 |
| Dolley, A | 2 |
| Cheung, WY | 2 |
| Matsumoto, T | 4 |
| Ikoma, T | 1 |
| Yamamura, S | 1 |
| Miura, K | 2 |
| Tsuduki, T | 1 |
| Watanabe, T | 4 |
| Nagai, H | 1 |
| Takatani, M | 1 |
| Yasui, H | 7 |
| Nevala-Plagemann, C | 1 |
| Sama, S | 1 |
| Ying, J | 1 |
| Shen, J | 1 |
| Haaland, B | 1 |
| Florou, V | 1 |
| Garrido-Laguna, I | 1 |
| Kobuchi, S | 4 |
| Tsuda, M | 1 |
| Okamura, M | 1 |
| Nakamura, T | 1 |
| Ito, Y | 5 |
| Okuda, H | 1 |
| Shimomura, M | 1 |
| Ikeda, S | 3 |
| Nakahara, M | 1 |
| Miguchi, M | 1 |
| Ishizaki, Y | 1 |
| Saitoh, Y | 1 |
| Toyota, K | 1 |
| Sumitani, D | 1 |
| Shimizu, Y | 1 |
| Takakura, Y | 1 |
| Shimizu, W | 1 |
| Yoshimitsu, M | 1 |
| Kodama, S | 1 |
| Fujimori, M | 1 |
| Oheda, M | 1 |
| Kobayashi, H | 1 |
| Ohdan, H | 1 |
| Victorino, APOS | 1 |
| Meton, F | 1 |
| Mardegan, L | 1 |
| Festa, J | 1 |
| Piranda, DN | 1 |
| Araujo, KB | 1 |
| Matsuoka, S | 2 |
| Fujii, H | 5 |
| Iihara, H | 3 |
| Ohata, K | 2 |
| Hirose, C | 3 |
| Watanabe, D | 3 |
| Sadaka, S | 1 |
| Kiyama, S | 2 |
| Makiyama, A | 6 |
| Takahashi, T | 10 |
| Kobayashi, R | 2 |
| Matsuhashi, N | 3 |
| Suzuki, A | 3 |
| Miyashita, S | 1 |
| Shimizu, T | 5 |
| Ishizuka, M | 1 |
| Niki, M | 1 |
| Nishi, Y | 1 |
| Shibuya, N | 1 |
| Hachiya, H | 1 |
| Sakuraoka, Y | 1 |
| Shiraki, T | 1 |
| Mori, S | 2 |
| Iso, Y | 1 |
| Irisawa, A | 1 |
| Aoki, T | 2 |
| Ghidini, M | 2 |
| Takahashi, O | 1 |
| Mansoor, W | 1 |
| Prager, GW | 3 |
| Fakih, M | 1 |
| Elez, E | 1 |
| Cruz, FM | 1 |
| Wyrwicz, L | 1 |
| Stroyakovskiy, D | 1 |
| Pápai, Z | 1 |
| Poureau, PG | 1 |
| Liposits, G | 1 |
| Bondarenko, I | 1 |
| Modest, DP | 1 |
| Leger, C | 1 |
| Vidot, L | 1 |
| Hayashi, K | 1 |
| Furuta, M | 1 |
| Furusawa, K | 1 |
| Hamaguchi, T | 3 |
| Watanabe, M | 6 |
| Inokuchi, Y | 1 |
| Onuma, S | 1 |
| Hashimoto, I | 1 |
| Suematsu, H | 1 |
| Nagasawa, S | 1 |
| Kanematsu, K | 1 |
| Yamada, T | 3 |
| Notsu, A | 1 |
| Ogata, T | 2 |
| Oshima, T | 1 |
| Machida, N | 3 |
| Furuse, J | 1 |
| Maeda, S | 1 |
| Kröning, H | 1 |
| Göhler, T | 1 |
| Decker, T | 1 |
| Grundeis, M | 1 |
| Kojouharoff, G | 1 |
| Lipke, J | 1 |
| Semsek, D | 1 |
| Moorahrend, E | 1 |
| Sauer, A | 1 |
| Bruch, HR | 1 |
| Liersch, R | 1 |
| Nusch, A | 1 |
| Vehling-Kaiser, U | 1 |
| Welslau, M | 1 |
| Grunewald, R | 1 |
| Harich, HD | 1 |
| Stephany, M | 1 |
| Uhlig, J | 1 |
| de Buhr, R | 1 |
| Frank, M | 1 |
| Hogrefe, C | 1 |
| Marschner, N | 1 |
| Potthoff, K | 1 |
| Hartmann, F | 1 |
| Reisländer, T | 1 |
| Schwaner, I | 1 |
| Taniguchi, H | 8 |
| Yamazaki, K | 14 |
| Masuishi, T | 7 |
| Kawakami, T | 2 |
| Onozawa, Y | 4 |
| Honda, K | 1 |
| Kadowaki, S | 4 |
| Narita, Y | 3 |
| Tsushima, T | 4 |
| Hamauchi, S | 3 |
| Todaka, A | 3 |
| Yokota, T | 3 |
| Ando, M | 4 |
| Mori, K | 3 |
| Shirasu, H | 1 |
| Muro, K | 11 |
| Koper, A | 1 |
| Wileński, S | 1 |
| Śledzińska, P | 1 |
| Bebyn, M | 1 |
| Koper, K | 1 |
| Voutsadakis, IA | 1 |
| Marques, D | 1 |
| Costa, AL | 1 |
| Mansinho, A | 1 |
| Quintela, A | 2 |
| Pratas, E | 1 |
| Brito-da-Silva, J | 1 |
| Cruz, J | 1 |
| Félix, J | 1 |
| Rodrigues, J | 1 |
| Mota, M | 1 |
| Teixeira, AR | 1 |
| Dâmaso, S | 1 |
| Pinheiro, S | 1 |
| Andreozzi, V | 1 |
| Costa, L | 1 |
| Barros, AG | 1 |
| Kagawa, Y | 1 |
| Shinozaki, E | 4 |
| Okude, R | 1 |
| Tone, T | 1 |
| Kunitomi, Y | 1 |
| Nakashima, M | 1 |
| Yoshida, N | 2 |
| Kuriu, Y | 1 |
| Ikeda, J | 2 |
| Kudou, M | 1 |
| Kirishima, T | 1 |
| Okayama, T | 1 |
| Miyagawa, K | 1 |
| Takagi, T | 1 |
| Nakanishi, M | 1 |
| Ishikawa, T | 4 |
| Itoh, Y | 1 |
| Otsuji, E | 1 |
| Okunaka, M | 1 |
| Kawazoe, A | 3 |
| Nakamura, H | 1 |
| Kotani, D | 5 |
| Mishima, S | 1 |
| Kuboki, Y | 4 |
| Nakamura, Y | 2 |
| Yu, YL | 1 |
| Tseng, WK | 1 |
| Liao, CK | 1 |
| Yeh, CY | 1 |
| Chen, HH | 1 |
| Liu, YH | 1 |
| Liaw, YW | 1 |
| Fan, CW | 1 |
| Shiroyama, M | 1 |
| Fukuoka, S | 6 |
| Kumekawa, Y | 4 |
| Kajiwara, T | 5 |
| Shimada, Y | 9 |
| Esaki, T | 8 |
| Moriwaki, T | 9 |
| Hishida, S | 1 |
| Tajima, JY | 1 |
| Samawi, HH | 1 |
| Brezden-Masley, C | 1 |
| Afzal, AR | 1 |
| Grothey, A | 4 |
| Marshall, JL | 1 |
| Bekaii-Saab, T | 2 |
| Chen, J | 1 |
| Lin, H | 1 |
| Peng, Y | 2 |
| Denda, T | 6 |
| Hatachi, Y | 2 |
| Suto, T | 3 |
| Sugimoto, N | 6 |
| Enomoto, M | 4 |
| Kashiwada, T | 3 |
| Oki, E | 5 |
| Komatsu, Y | 8 |
| Tsuji, A | 7 |
| Tsuchihashi, K | 2 |
| Sakai, D | 4 |
| Ueno, H | 3 |
| Tamura, T | 3 |
| Yamashita, K | 3 |
| Zhang, Q | 1 |
| Wang, Q | 1 |
| Wang, X | 2 |
| Peng, Z | 1 |
| Horasawa, S | 1 |
| Kaneko, A | 1 |
| Bando, H | 3 |
| Kojima, T | 2 |
| Kasi, PM | 2 |
| Cleary, JM | 2 |
| Nishina, T | 7 |
| Garcia-Carbonero, R | 4 |
| Baba, H | 8 |
| Argilés, G | 4 |
| Sobrero, A | 4 |
| Yamaguchi, K | 7 |
| Peeters, M | 3 |
| Zaniboni, A | 4 |
| Tsuji, Y | 4 |
| Hochster, HS | 6 |
| Tran, B | 2 |
| Hamada, C | 2 |
| Tanase, T | 3 |
| Benedetti, F | 3 |
| Yamashita, F | 1 |
| Lenz, HJ | 7 |
| André, T | 2 |
| Saunders, M | 2 |
| Kanehisa, A | 1 |
| Gandossi, E | 1 |
| Amellal, NC | 1 |
| Pfeiffer, P | 4 |
| Yilmaz, M | 1 |
| Möller, S | 1 |
| Zitnjak, D | 1 |
| Krogh, M | 1 |
| Petersen, LN | 1 |
| Poulsen, LØ | 1 |
| Winther, SB | 1 |
| Thomsen, KG | 1 |
| Qvortrup, C | 1 |
| Carter, AM | 1 |
| Spooner, C | 1 |
| Stevens, D | 1 |
| Mullamitha, S | 1 |
| Yoshida, Y | 2 |
| Hashimoto, Y | 1 |
| Miyazaki, M | 1 |
| Aisu, N | 2 |
| Kajitani, R | 2 |
| Munechika, T | 2 |
| Matsumoto, Y | 4 |
| Nagano, H | 1 |
| Shimaoka, H | 1 |
| Komono, A | 2 |
| Sakamoto, R | 2 |
| Yoshimatsu, G | 1 |
| Yoshimura, F | 1 |
| Kiyomi, F | 2 |
| Hasegawa, S | 3 |
| Siebenhüner, A | 2 |
| De Dosso, S | 1 |
| Meisel, A | 1 |
| Wagner, AD | 1 |
| Borner, M | 3 |
| Kitahora, M | 1 |
| Yamada, Y | 7 |
| Ishihara, T | 1 |
| Yoshida, K | 4 |
| Price, T | 4 |
| Burge, M | 1 |
| Chantrill, L | 1 |
| Pavlakis, N | 1 |
| Shapiro, J | 1 |
| Sjoquist, K | 1 |
| Kawamoto, Y | 1 |
| Muranaka, T | 1 |
| Tajika, M | 3 |
| Nakatsumi, H | 1 |
| Yuki, S | 1 |
| Omae, K | 1 |
| Bonetti, A | 2 |
| Ogata, M | 1 |
| Kotaka, M | 1 |
| Kato, T | 7 |
| Satake, H | 3 |
| Shibutani, M | 1 |
| Nagahara, H | 1 |
| Fukuoka, T | 1 |
| Iseki, Y | 1 |
| Wang, EN | 1 |
| Okazaki, Y | 1 |
| Kashiwagi, S | 1 |
| Maeda, K | 3 |
| Hirakawa, K | 1 |
| Ohira, M | 1 |
| Walter, T | 1 |
| Hawkins, NS | 1 |
| Pollock, RF | 1 |
| Colaone, F | 1 |
| Shergill, S | 1 |
| Chen, TC | 1 |
| Jeng, YM | 1 |
| Liang, JT | 1 |
| Hamada, S | 1 |
| Komatsu, S | 1 |
| Shibata, R | 1 |
| Konishi, T | 1 |
| Matsubara, D | 1 |
| Soga, K | 1 |
| Shimomura, K | 2 |
| Taniguchi, F | 1 |
| Shioaki, Y | 1 |
| Shiraiwa, K | 1 |
| Suzuki, Y | 1 |
| Uchida, H | 1 |
| Iwashita, Y | 1 |
| Tanaka, R | 1 |
| Iwao, M | 1 |
| Tada, K | 1 |
| Hirashita, T | 1 |
| Masuda, T | 1 |
| Endo, Y | 1 |
| Inomata, M | 1 |
| Itoh, H | 1 |
| Maeda, F | 1 |
| Gan, S | 1 |
| Yamada, A | 2 |
| Kajiyama, D | 1 |
| Tokitou, F | 1 |
| Kawaguchi, M | 1 |
| Amagasa, H | 1 |
| Motoyama, K | 1 |
| Ganno, H | 1 |
| Imai, K | 1 |
| Ami, K | 1 |
| Iida, S | 2 |
| Fukuda, A | 1 |
| Okano, Y | 1 |
| Court, OR | 1 |
| Shemilt, K | 1 |
| Takushima, Y | 1 |
| Igarashi, A | 1 |
| Yoshihara, H | 1 |
| Zaanan, A | 1 |
| Lorenzen, S | 1 |
| Fornaro, L | 1 |
| Catenacci, DVT | 1 |
| Moreno, SR | 1 |
| Azcue, P | 1 |
| Alsina, M | 1 |
| Vitale, P | 1 |
| Zanaletti, N | 1 |
| Cervantes, A | 4 |
| Rosellò, S | 1 |
| Fenocchio, E | 1 |
| Milanesio, M | 1 |
| Lombardi, P | 1 |
| Suenaga, M | 2 |
| Schirripa, M | 3 |
| Cao, S | 6 |
| Zhang, W | 2 |
| Yang, D | 2 |
| Murgioni, S | 2 |
| Mennitto, A | 2 |
| Ning, Y | 2 |
| Okazaki, S | 2 |
| Berger, MD | 2 |
| Miyamoto, Y | 5 |
| Gopez, R | 2 |
| Barzi, A | 3 |
| Yamaguchi, T | 6 |
| Loupakis, F | 4 |
| Miyake, Y | 2 |
| Nishimura, J | 2 |
| Ikeda, M | 3 |
| Tsujie, M | 2 |
| Hata, T | 3 |
| Takemasa, I | 2 |
| Mizushima, T | 4 |
| Yamamoto, H | 2 |
| Sekimoto, M | 2 |
| Nezu, R | 2 |
| Doki, Y | 3 |
| Mori, M | 4 |
| Pan, W | 1 |
| Li, Y | 1 |
| Feng, Y | 1 |
| Yang, F | 1 |
| Liu, H | 1 |
| Chionh, F | 1 |
| Lau, D | 1 |
| Yeung, Y | 1 |
| Tebbutt, N | 1 |
| Okamoto, W | 2 |
| Mochizuki, N | 1 |
| Nomura, S | 2 |
| Sato, A | 2 |
| Makiyama, C | 1 |
| Sugiyama, M | 2 |
| Okuyama, H | 2 |
| Baba, E | 3 |
| Gosho, M | 1 |
| Baratelli, C | 1 |
| Tampellini, M | 1 |
| Di Maio, M | 1 |
| Ottone, A | 1 |
| Brizzi, MP | 1 |
| Forti, L | 1 |
| Alabiso, I | 1 |
| Sonetto, C | 1 |
| Alabiso, O | 1 |
| Scagliotti, GV | 1 |
| Dadduzio, V | 1 |
| Salvatore, L | 2 |
| Bullement, A | 1 |
| Underhill, S | 1 |
| Hatswell, AJ | 1 |
| Abrahao, ABK | 1 |
| Ko, YJ | 1 |
| Berry, S | 1 |
| Chan, KKW | 1 |
| Buscaglia, M | 1 |
| Bendell, JC | 2 |
| Kopetz, S | 3 |
| Bebeau, P | 1 |
| Ramaekers, BLT | 1 |
| Wolff, R | 1 |
| van Giessen, A | 1 |
| Pouwels, X | 1 |
| Fayter, D | 1 |
| Lang, S | 1 |
| Armstrong, N | 1 |
| Worthy, G | 1 |
| Duffy, S | 1 |
| Kleijnen, J | 1 |
| Joore, MA | 1 |
| Kwakman, JJM | 1 |
| Vink, G | 1 |
| Vestjens, JH | 1 |
| Beerepoot, LV | 1 |
| de Groot, JW | 1 |
| Jansen, RL | 1 |
| Opdam, FL | 2 |
| Boot, H | 1 |
| Creemers, GJ | 1 |
| van Rooijen, JM | 1 |
| Los, M | 1 |
| Vulink, AJE | 1 |
| Schut, H | 1 |
| van Meerten, E | 1 |
| Baars, A | 1 |
| Hamberg, P | 1 |
| Kapiteijn, E | 1 |
| Sommeijer, DW | 1 |
| Punt, CJA | 1 |
| Koopman, M | 2 |
| Nakanishi, R | 1 |
| Kitao, H | 2 |
| Kiniwa, M | 1 |
| Morodomi, Y | 1 |
| Iimori, M | 2 |
| Kurashige, J | 1 |
| Nakashima, Y | 1 |
| Saeki, H | 3 |
| Maehara, Y | 4 |
| Xu, J | 1 |
| Pan, H | 1 |
| Xu, R | 1 |
| Guo, W | 1 |
| Han, SW | 2 |
| Liu, T | 1 |
| Park, YS | 1 |
| Shi, C | 1 |
| Bai, Y | 1 |
| Bi, F | 1 |
| Ahn, JB | 1 |
| Qin, S | 1 |
| Li, Q | 1 |
| Wu, C | 1 |
| Ma, D | 1 |
| Lin, D | 2 |
| Burki, TK | 1 |
| Kusumoto, T | 1 |
| Sunami, E | 1 |
| Ota, M | 1 |
| Sakamoto, Y | 1 |
| Tomita, N | 3 |
| Maeda, A | 1 |
| Mochizuki, I | 1 |
| Okabe, M | 1 |
| Kunieda, K | 1 |
| Yamauchi, J | 1 |
| Itabashi, M | 2 |
| Kotake, K | 1 |
| Takahashi, K | 5 |
| Aiba, K | 2 |
| Ishiguro, M | 1 |
| Morita, S | 2 |
| Sugihara, K | 6 |
| Laurent, S | 1 |
| Winkler, R | 2 |
| Grávalos, C | 2 |
| Benavides, M | 1 |
| Longo-Munoz, F | 2 |
| Portales, F | 1 |
| Siena, S | 1 |
| Loehrer, P | 1 |
| Jacobs, BAW | 1 |
| Snoeren, N | 1 |
| Samim, M | 1 |
| Rosing, H | 1 |
| de Vries, N | 1 |
| Deenen, MJ | 1 |
| Beijnen, JH | 1 |
| Schellens, JHM | 1 |
| van Hillegersberg, R | 1 |
| Kimura, M | 3 |
| Usami, E | 3 |
| Iwai, M | 2 |
| Teramachi, H | 2 |
| Yoshimura, T | 3 |
| Arnold, D | 1 |
| Stein, A | 1 |
| Moreno Vera, S | 1 |
| Mounedji, N | 1 |
| Mulet, N | 1 |
| Matos, I | 1 |
| Noguerido, A | 1 |
| Élez, ME | 2 |
| Yasue, F | 1 |
| Kawachi, S | 1 |
| Mitsuoka, M | 1 |
| Ikeda, Y | 1 |
| Sun, R | 1 |
| Horiguchi, M | 1 |
| Wei, LJ | 1 |
| Kawahara, H | 3 |
| Mouri, T | 1 |
| Ishida, K | 3 |
| Matsumoto, N | 1 |
| Akiba, T | 1 |
| Yanaga, K | 1 |
| Lonardi, S | 2 |
| Noventa, S | 1 |
| Tamburini, E | 2 |
| Frassineti, GL | 1 |
| Mosconi, S | 4 |
| Nichetti, F | 1 |
| Zucchelli, G | 1 |
| Dal Maso, A | 1 |
| Sforza, V | 1 |
| Di Bartolomeo, M | 3 |
| Miceli, R | 2 |
| Martinez-Perez, J | 1 |
| Riesco-Martinez, MC | 1 |
| Patel, AK | 1 |
| Duh, MS | 1 |
| Barghout, V | 1 |
| Yenikomshian, MA | 1 |
| Xiao, Y | 1 |
| Wynant, W | 1 |
| Tabesh, M | 1 |
| Fuchs, CS | 1 |
| Chu, E | 2 |
| Daibo, K | 1 |
| Unseld, M | 1 |
| Drimmel, M | 1 |
| Gleiss, A | 1 |
| Bianconi, D | 1 |
| Kieler, M | 1 |
| Scheithauer, W | 3 |
| Winder, T | 1 |
| Ito, M | 2 |
| Katsumata, K | 1 |
| Kishimoto, J | 1 |
| Takayama, T | 4 |
| Hamamoto, Y | 1 |
| Goto, M | 2 |
| Nakayama, N | 1 |
| Cho, SK | 1 |
| Hay, JW | 1 |
| Cohen, SJ | 1 |
| Shinmura, K | 1 |
| Kato, H | 1 |
| Kawanishi, Y | 1 |
| Tao, H | 1 |
| Yoshimura, K | 1 |
| Nakamura, S | 2 |
| Misawa, K | 1 |
| Sugimura, H | 1 |
| Hiyoshi, Y | 1 |
| Akiyama, T | 1 |
| Kiyozumi, Y | 1 |
| Eto, K | 1 |
| Yohei, N | 1 |
| Iwagami, S | 1 |
| Baba, Y | 1 |
| Hsu, TC | 1 |
| Wang, CC | 1 |
| Wang, Y | 1 |
| Zhang, X | 1 |
| Zou, G | 1 |
| Peng, S | 1 |
| Liu, C | 1 |
| Zhou, X | 1 |
| Ou, J | 1 |
| Yang, W | 1 |
| Zhang, Y | 1 |
| Hao, J | 1 |
| Li, F | 1 |
| Chen, Y | 1 |
| Zhao, Y | 1 |
| Xie, X | 1 |
| Wu, S | 1 |
| Zha, L | 1 |
| Luo, X | 1 |
| Xie, G | 1 |
| Wang, L | 1 |
| Sun, W | 2 |
| Zhou, Q | 1 |
| Liang, H | 1 |
| Sadahiro, S | 10 |
| Suzuki, T | 10 |
| Tanaka, A | 3 |
| Okada, K | 6 |
| Saito, G | 1 |
| Miyakita, H | 1 |
| Chan, LF | 1 |
| Kamei, Y | 1 |
| Kajiwara, H | 1 |
| Nagase, H | 3 |
| Fernandez Montes, A | 1 |
| Vazquez Rivera, F | 1 |
| Martinez Lago, N | 1 |
| Covela Rúa, M | 1 |
| Cousillas Castiñeiras, A | 1 |
| Gonzalez Villarroel, P | 1 |
| Méndez Méndez, JC | 1 |
| Salgado Fernández, M | 1 |
| Candamio Folgar, S | 1 |
| Reboredo López, M | 1 |
| Carmona Campos, M | 1 |
| Gallardo Martín, E | 1 |
| Jorge Fernández, M | 1 |
| Pellón Augusto, ML | 1 |
| París Bouzas, L | 1 |
| García Gómez, J | 1 |
| Sonbol, MB | 1 |
| Benkhadra, R | 1 |
| Wang, Z | 1 |
| Firwana, B | 1 |
| Walden, DJ | 1 |
| Mody, K | 1 |
| Hubbard, JM | 1 |
| Murad, MH | 1 |
| Ahn, DH | 1 |
| Chan, BM | 1 |
| Matsuda, A | 1 |
| Matsumoto, S | 2 |
| Sakurazawa, N | 1 |
| Kawano, Y | 1 |
| Shinozuka, E | 1 |
| Sekiguchi, K | 1 |
| Suzuki, H | 2 |
| Yoshida, H | 1 |
| Imoto, K | 3 |
| Kuwano, S | 3 |
| Takada, K | 3 |
| Perrone, F | 1 |
| Dotti, KF | 1 |
| Lampis, A | 1 |
| Bertan, C | 1 |
| Beretta, E | 1 |
| Rimassa, L | 2 |
| Carbone, C | 1 |
| Biondani, P | 1 |
| Passalacqua, R | 1 |
| Pilotti, S | 1 |
| Bajetta, E | 2 |
| Nishimura, A | 1 |
| Shibata, N | 1 |
| Kamijo, A | 2 |
| Uchida, J | 5 |
| Sunaga, T | 1 |
| Suzuki, S | 1 |
| Kogo, M | 1 |
| Kurihara, T | 1 |
| Kaji, S | 1 |
| Koike, N | 1 |
| Harada, N | 1 |
| Suzuki, M | 1 |
| Kiuchi, Y | 1 |
| Totsuka, O | 1 |
| Kawate, S | 2 |
| Hirai, K | 3 |
| Ogawa, H | 1 |
| Toya, H | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 2 |
| Sugiura, F | 4 |
| Inoue, K | 3 |
| Kogita, A | 2 |
| Yoshioka, Y | 2 |
| Hida, J | 3 |
| Okuno, K | 5 |
| Sukegawa, Y | 3 |
| Mizuta, M | 2 |
| Watanabe, R | 1 |
| Takahashi, I | 2 |
| Watanabe, Y | 5 |
| Maeba, T | 2 |
| Hyodo, I | 3 |
| Saiura, A | 2 |
| Yamamoto, J | 2 |
| Hasegawa, K | 4 |
| Oba, M | 2 |
| Miyagawa, S | 2 |
| Ijichi, M | 2 |
| Teruya, M | 2 |
| Yoshimi, F | 2 |
| Kawasaki, S | 2 |
| Koyama, H | 2 |
| Makuuchi, M | 2 |
| Kokudo, N | 3 |
| Draoui, N | 1 |
| Schicke, O | 1 |
| Seront, E | 1 |
| Bouzin, C | 1 |
| Sonveaux, P | 1 |
| Riant, O | 1 |
| Feron, O | 1 |
| Yoshinaga, K | 1 |
| Morita, M | 1 |
| Ikeda, T | 1 |
| Sugimachi, K | 2 |
| Yamashita, Y | 2 |
| Ikegami, T | 1 |
| Uchiyama, H | 1 |
| Yoshizumi, T | 1 |
| Soejima, Y | 1 |
| Kawanaka, H | 1 |
| Mimori, K | 1 |
| Lee, KW | 1 |
| Kim, YJ | 1 |
| Lee, KH | 1 |
| Kim, TY | 2 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Bang, YJ | 1 |
| Choi, IS | 1 |
| Kim, JH | 2 |
| Mizusawa, J | 1 |
| Saito, N | 3 |
| Kanemitsu, Y | 1 |
| Takiguchi, N | 1 |
| Ohue, M | 2 |
| Takii, Y | 2 |
| Sato, T | 4 |
| Yamaguchi, S | 5 |
| Akaike, M | 1 |
| Mishima, H | 1 |
| Kubo, Y | 1 |
| Nakamura, K | 1 |
| Fukuda, H | 1 |
| Moriya, Y | 2 |
| Carlsson, G | 2 |
| Odin, E | 2 |
| Gustavsson, B | 2 |
| Wettergren, Y | 2 |
| Nukatsuka, M | 2 |
| Nakagawa, F | 4 |
| Saito, H | 1 |
| Sakata, M | 1 |
| Takechi, T | 3 |
| Tsukihara, H | 1 |
| Sakamoto, K | 4 |
| Tanaka, N | 2 |
| Okabe, H | 2 |
| Matsuo, K | 2 |
| Yoshisue, K | 1 |
| Chiba, M | 1 |
| Nakanishi, T | 1 |
| Tamai, I | 1 |
| Yokogawa, T | 1 |
| Oguchi, K | 1 |
| Kazuno, H | 1 |
| Osada, A | 1 |
| van Staveren, MC | 1 |
| Opdam, F | 1 |
| Guchelaar, HJ | 1 |
| van Kuilenburg, AB | 1 |
| Maring, JG | 1 |
| Gelderblom, H | 1 |
| Tamagawa, H | 1 |
| Matsuda, C | 1 |
| Murata, K | 2 |
| Fukunaga, M | 3 |
| Ota, H | 1 |
| Hasegawa, J | 1 |
| Fukuzaki, T | 1 |
| Mizunuma, N | 3 |
| Boucher, E | 1 |
| Prenen, H | 1 |
| Mizuguchi, H | 3 |
| Mayor, S | 1 |
| Cleghorn, S | 1 |
| Sasaki, K | 3 |
| Ohge, H | 1 |
| Tsuchiya, T | 1 |
| Kondo, K | 2 |
| Ogata, Y | 3 |
| Masuko, H | 1 |
| Hamada, M | 1 |
| Nishimura, G | 2 |
| Taguri, M | 1 |
| Kodaira, S | 3 |
| Fuse, N | 1 |
| Koizumi, W | 1 |
| Shimada, K | 1 |
| Takinishi, Y | 1 |
| Rosen, LS | 1 |
| Goldman, JW | 1 |
| Infante, JR | 1 |
| Zergebel, C | 1 |
| Patel, MR | 1 |
| Yoshimatsu, K | 2 |
| Yokomizo, H | 2 |
| Nakayama, M | 1 |
| Okayama, S | 1 |
| Satake, M | 1 |
| Sakuma, A | 1 |
| Yano, Y | 1 |
| Matsumoto, A | 1 |
| Fujimoto, T | 2 |
| Usui, T | 1 |
| Shiozawa, S | 1 |
| Shimakawa, T | 1 |
| Katsube, T | 1 |
| Naritaka, Y | 1 |
| Sanz-Garcia, E | 1 |
| Grasselli, J | 1 |
| Uboha, N | 1 |
| Shimada, M | 1 |
| Higashijima, J | 1 |
| Sakai, Y | 1 |
| Ozeki, M | 1 |
| Amagai, K | 2 |
| Negoro, Y | 1 |
| Indo, S | 1 |
| Sato, M | 1 |
| Yamamoto, Y | 2 |
| Nakajima, G | 1 |
| Hiroshima, Y | 1 |
| Ishida, H | 6 |
| Matsuoka, K | 1 |
| Tokunaga, E | 1 |
| Maruyama, T | 1 |
| Yasuda, K | 1 |
| Sako, A | 1 |
| Ueda, K | 2 |
| Okumura, M | 1 |
| Goldberg, R | 1 |
| Arita, S | 2 |
| Shirakawa, T | 1 |
| Matsushita, Y | 1 |
| Shimokawa, HK | 1 |
| Hirano, G | 1 |
| Shibata, Y | 1 |
| Tamura, S | 1 |
| Mitsugi, K | 1 |
| Ariyama, H | 1 |
| Kusaba, H | 1 |
| Akashi, K | 1 |
| Sasaki, Y | 2 |
| Akasu, T | 2 |
| Kojima, H | 1 |
| Matsuda, K | 1 |
| Nakamori, S | 1 |
| Komori, K | 1 |
| Nagashima, K | 1 |
| van der Velden, DL | 1 |
| Voest, EE | 1 |
| Takahashi, S | 1 |
| Kuno, H | 1 |
| Mota, JM | 1 |
| Fonseca, LG | 1 |
| Braghiroli, MI | 1 |
| Hoff, PM | 11 |
| Uetake, H | 5 |
| Fujita, N | 1 |
| Furuta, T | 1 |
| Katori, J | 1 |
| Hara, N | 1 |
| Petrelli, F | 3 |
| Barni, S | 2 |
| Bertocchi, P | 2 |
| Cecchini, M | 1 |
| Ramanathan, RK | 1 |
| Pericay, C | 1 |
| Gil-Calle, S | 1 |
| Carrato-Mena, A | 1 |
| Limón, ML | 1 |
| Sueda, T | 1 |
| Kudo, T | 1 |
| Sugiura, T | 1 |
| Takahashi, H | 1 |
| Haraguchi, N | 1 |
| Hayashi, T | 1 |
| Satoh, T | 1 |
| Kito, Y | 2 |
| Komori, A | 2 |
| Ishihara, M | 2 |
| Tanaka, T | 2 |
| Fukutomi, A | 2 |
| Ura, T | 2 |
| Giampieri, R | 1 |
| Restivo, A | 1 |
| Pusceddu, V | 1 |
| Del Prete, M | 1 |
| Maccaroni, E | 1 |
| Bittoni, A | 1 |
| Faloppi, L | 1 |
| Andrikou, K | 1 |
| Bianconi, M | 1 |
| Cabras, F | 1 |
| Berardi, R | 1 |
| Zorcolo, L | 1 |
| Scintu, F | 1 |
| Cascinu, S | 1 |
| Scartozzi, M | 1 |
| Takahashi, M | 1 |
| Matsuyama, Y | 1 |
| Kamei, H | 1 |
| Ishibashi, N | 3 |
| Tanigawa, M | 1 |
| Uchida, M | 1 |
| Akagi, Y | 2 |
| Aprile, G | 1 |
| Bozzarelli, S | 1 |
| Antonuzzo, L | 1 |
| Morano, F | 1 |
| Battaglin, F | 1 |
| Baretti, M | 1 |
| Berenato, R | 1 |
| Formica, V | 1 |
| Spada, D | 1 |
| Cinieri, S | 1 |
| Beretta, G | 1 |
| de Braud, F | 1 |
| Lee, JJ | 1 |
| Fujii, M | 5 |
| Kochi, M | 1 |
| Ben Fredj, R | 1 |
| Gross, E | 1 |
| Ben Ahmed, S | 1 |
| Hassine, H | 1 |
| Saguem, S | 1 |
| Thomas, MB | 1 |
| Langleben, A | 1 |
| Rinaldi, D | 1 |
| Anthony, L | 1 |
| Wolff, RA | 2 |
| Lassere, Y | 4 |
| Abbruzzese, JL | 5 |
| Sakai, T | 1 |
| Maekawa, T | 1 |
| Mikami, K | 1 |
| Hoshino, S | 1 |
| Shirakusa, T | 1 |
| Overman, MJ | 1 |
| Varadhachary, G | 1 |
| Fukushima, M | 2 |
| Kuwata, K | 1 |
| Mita, A | 1 |
| Hoff, P | 1 |
| Xiong, H | 1 |
| Kameyama, H | 1 |
| Nomura, T | 1 |
| Nakagawa, S | 1 |
| Yabusaki, H | 1 |
| Tsuchiya, Y | 1 |
| Nashimoto, A | 1 |
| Tanaka, O | 1 |
| Idelevich, E | 1 |
| Greif, F | 1 |
| Mavor, E | 1 |
| Miller, R | 1 |
| Kashtan, H | 1 |
| Susmalian, S | 1 |
| Ariche, A | 1 |
| Brenner, B | 1 |
| Baruch, NB | 1 |
| Dinerman, M | 1 |
| Shani, A | 1 |
| Yoshitani, S | 1 |
| Takashima, S | 1 |
| Bennouna, J | 4 |
| Douillard, JY | 6 |
| Hattori, T | 1 |
| Mine, T | 1 |
| Komatsu, N | 1 |
| Itoh, K | 1 |
| Shiozaki, H | 1 |
| Takemoto, H | 1 |
| Furukawa, H | 2 |
| Okita, NT | 1 |
| Takahari, D | 1 |
| Hirashima, Y | 1 |
| Matsubara, J | 1 |
| Kato, K | 2 |
| Shirao, K | 2 |
| Shimoda, T | 1 |
| Hazra, A | 1 |
| Selhub, J | 2 |
| Chao, WH | 1 |
| Ueland, PM | 1 |
| Hunter, DJ | 1 |
| Baron, JA | 1 |
| Furuhata, T | 1 |
| Meguro, M | 1 |
| Nishidate, T | 1 |
| Okita, K | 1 |
| Ishiyama, G | 1 |
| Iwayama, Y | 1 |
| Hosokawa, Y | 1 |
| Tsuruma, T | 1 |
| Kimura, Y | 1 |
| Mizuguchi, T | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Tsunoda, A | 5 |
| Nakao, K | 4 |
| Matsui, N | 3 |
| Tsunoda, Y | 2 |
| Spector, T | 4 |
| Matsumoto, H | 3 |
| Yasutome, M | 1 |
| Mori, T | 3 |
| Ooyama, A | 1 |
| Kusano, M | 1 |
| Nishigaki, T | 1 |
| Ide, Y | 1 |
| Bellot, GL | 1 |
| Tan, WH | 1 |
| Tay, LL | 1 |
| Koh, D | 1 |
| Tokoro, T | 1 |
| Ishimaru, E | 1 |
| Büchel, B | 1 |
| Rhyn, P | 1 |
| Schürch, S | 1 |
| Bühr, C | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Francois, E | 4 |
| Smith, D | 2 |
| Dahan, L | 1 |
| Michel, C | 1 |
| Perrier, H | 3 |
| Mari, V | 1 |
| Seitz, JF | 3 |
| Follana, P | 1 |
| Evesque, L | 1 |
| Chamorey, E | 1 |
| Peters, GJ | 2 |
| Bijnsdorp, IV | 1 |
| Matsushita, N | 1 |
| Aruga, A | 1 |
| Inoue, Y | 1 |
| Kotera, Y | 1 |
| Takeda, K | 1 |
| Yamamoto, M | 1 |
| Kim, K | 1 |
| Nam, E | 1 |
| Lee, NS | 1 |
| Lee, HR | 2 |
| Lee, JY | 1 |
| Park, SH | 1 |
| Oh, SY | 1 |
| Song, SY | 1 |
| Park, JO | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Lee, MH | 1 |
| Lee, WY | 1 |
| Chun, H | 1 |
| Park, CH | 1 |
| Park, K | 1 |
| Kang, WK | 1 |
| Friedman, M | 1 |
| Skillings, JR | 2 |
| Eisenberg, P | 1 |
| Davidson, N | 1 |
| Harper, P | 1 |
| Vincent, MD | 1 |
| Lembersky, BC | 1 |
| Thompson, S | 1 |
| Maniero, A | 1 |
| Benner, SE | 2 |
| Carmichael, J | 2 |
| Popiela, T | 1 |
| Radstone, D | 1 |
| Falk, S | 1 |
| Oza, A | 2 |
| Skovsgaard, T | 1 |
| Munier, S | 1 |
| Martin, C | 4 |
| Caradonna, S | 1 |
| Muller-Weeks, S | 1 |
| Sugiyama, Y | 1 |
| Nakazato, H | 2 |
| Ito, K | 1 |
| Mizuno, I | 1 |
| Kanemitsu, T | 1 |
| Matsumoto, K | 1 |
| Yamaguchi, A | 4 |
| Nakai, K | 1 |
| Inada, K | 1 |
| Tatematsu, M | 1 |
| Fishman, AD | 1 |
| Wadler, S | 2 |
| Aranda, E | 4 |
| Antón-Torres, A | 1 |
| Sastre, J | 3 |
| Navarro, M | 3 |
| Rivera, F | 1 |
| Carrato, A | 3 |
| Bretón, JJ | 1 |
| Aparicio, J | 2 |
| Fernández-Martos, C | 2 |
| Díaz-Rubio, E | 4 |
| Leichman, CG | 2 |
| Chansky, K | 1 |
| Macdonald, JS | 1 |
| Doukas, MA | 1 |
| Budd, GT | 1 |
| Giguere, JK | 1 |
| Marsh, JC | 1 |
| Catalano, P | 1 |
| Huang, J | 1 |
| Graham, DL | 1 |
| Cornfeld, MJ | 1 |
| O'Dwyer, PJ | 2 |
| Benson, AB | 3 |
| Schilsky, RL | 5 |
| Maruyama, M | 2 |
| Ebuchi, M | 2 |
| Nagahama, T | 1 |
| Takashima, I | 2 |
| Ochiai, T | 1 |
| Natui, S | 1 |
| Kohnoe, S | 1 |
| Kakeji, Y | 1 |
| Glimelius, B | 2 |
| Porschen, R | 1 |
| Mackay, HJ | 1 |
| Twelves, C | 3 |
| Glasspool, R | 1 |
| Campbell, S | 1 |
| Massey, A | 1 |
| Macham, MA | 1 |
| Uzzel, M | 1 |
| Bailey, SM | 1 |
| Cunningham, D | 3 |
| Heslin, MJ | 1 |
| Yan, J | 1 |
| Weiss, H | 1 |
| Shao, L | 1 |
| Owens, J | 1 |
| Lucas, VS | 1 |
| Diasio, RB | 2 |
| Ohwada, S | 2 |
| Ikeya, T | 1 |
| Yokomori, T | 1 |
| Kusaba, T | 1 |
| Roppongi, T | 1 |
| Kawashima, Y | 1 |
| Nakajima, T | 2 |
| Morishita, Y | 1 |
| Isomoto, H | 2 |
| Tomita, M | 4 |
| Ogawa, M | 2 |
| Yamada, K | 1 |
| Nakagoe, T | 4 |
| Takano, S | 2 |
| Kakegawa, T | 1 |
| Maroun, J | 2 |
| Asche, C | 1 |
| Romeyer, F | 1 |
| Mukherjee, J | 1 |
| Cripps, C | 1 |
| Skillings, J | 1 |
| Letarte, J | 1 |
| Ichikawa, W | 2 |
| Shirota, Y | 2 |
| Yamada, H | 5 |
| Nihei, Z | 2 |
| Hirayama, R | 2 |
| Hosokawa, A | 1 |
| Miyamoto, H | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Ward, S | 1 |
| Kaltenthaler, E | 2 |
| Cowan, J | 2 |
| Brewer, N | 1 |
| Shirakawa, K | 2 |
| Nakada, H | 3 |
| Ohsawa, T | 2 |
| Takeuchi, I | 2 |
| Okada, N | 1 |
| Yokoyama, M | 3 |
| Inokuma, S | 3 |
| Odaka, A | 2 |
| Hoshino, T | 1 |
| Murata, N | 2 |
| Hashimoto, D | 2 |
| Itoyama, S | 1 |
| Miura, T | 2 |
| Higuchi, T | 2 |
| Petrioli, R | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Messinese, S | 1 |
| Correale, P | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Marzocca, G | 1 |
| Lorenzi, M | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Cats, A | 1 |
| Funahashi, K | 1 |
| Koike, J | 1 |
| Miki, T | 1 |
| Ryu, M | 1 |
| Shiokawa, H | 1 |
| Tokuyama, T | 1 |
| Goto, T | 1 |
| Teramoto, T | 2 |
| Emura, T | 1 |
| Murakami, Y | 1 |
| Kitazato, K | 1 |
| Folprecht, G | 1 |
| Köhne, CH | 2 |
| Choi, SW | 1 |
| Friso, S | 1 |
| Ghandour, H | 1 |
| Bagley, PJ | 1 |
| Mason, JB | 2 |
| Sakuyama, T | 1 |
| Takao, Y | 1 |
| Sato, K | 2 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Alliot, C | 2 |
| Gyldenkerne, N | 1 |
| Frödin, JE | 1 |
| Kjaer, M | 2 |
| Hansen, F | 3 |
| Keldsen, N | 2 |
| Sandberg, E | 3 |
| Jakobsen, A | 4 |
| Loehrer, PJ | 1 |
| Wadleigh, RG | 1 |
| Nagashima, F | 1 |
| Narayanan, S | 2 |
| McConnell, J | 1 |
| Little, J | 1 |
| Sharp, L | 1 |
| Piyathilake, CJ | 1 |
| Powers, H | 1 |
| Basten, G | 1 |
| Duthie, SJ | 2 |
| Labianca, R | 2 |
| Beretta, GD | 2 |
| Milesi, L | 1 |
| Feliu, J | 3 |
| Vicent, JM | 1 |
| García-Girón, C | 2 |
| Constela, M | 1 |
| Fonseca, E | 1 |
| Lomas, M | 1 |
| Antón-Aparicio, L | 1 |
| Dorta, FJ | 1 |
| Gonzalez-Baron, M | 2 |
| Katsuno, H | 1 |
| Utsumi, T | 2 |
| Hanai, T | 1 |
| Sato, H | 1 |
| Masumori, K | 1 |
| Koide, Y | 1 |
| Matsumoto, M | 2 |
| Maruyama, S | 1 |
| Koide, A | 1 |
| Ohbu, M | 1 |
| Tsunozaki, H | 1 |
| Yasuno, M | 1 |
| Lima, AP | 1 |
| del Giglio, A | 1 |
| Méndez, M | 1 |
| Alfonso, PG | 1 |
| Pujol, E | 1 |
| González, E | 1 |
| Castañon, C | 1 |
| Cerezuela, P | 1 |
| López-Mateos, Y | 1 |
| Cruz, JJ | 1 |
| Kono, T | 1 |
| Ebisawa, Y | 1 |
| Tomita, I | 1 |
| Chisato, N | 1 |
| Kamiya, K | 1 |
| Asama, T | 1 |
| Ayabe, T | 1 |
| Ashida, T | 1 |
| Kohgo, Y | 1 |
| Kasai, S | 1 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Wakai, T | 1 |
| Yokoyama, N | 1 |
| Okumura, S | 1 |
| Hatakeyama, K | 1 |
| Kawashima, K | 1 |
| Hatano, E | 1 |
| Satoh, S | 1 |
| Ikai, I | 1 |
| Shimahara, Y | 1 |
| Rosati, G | 1 |
| Cordio, S | 1 |
| Tucci, A | 1 |
| Blanco, G | 1 |
| Bordonaro, R | 1 |
| Reggiardo, G | 1 |
| Manzione, L | 1 |
| Matono, K | 1 |
| Sasatomi, T | 1 |
| Ohkita, A | 1 |
| Mizobe, T | 1 |
| Ogo, S | 1 |
| Ozasa, H | 1 |
| Shirouzu, K | 2 |
| Yoshino, S | 1 |
| Hazama, S | 1 |
| Shimizu, R | 1 |
| Fukuda, S | 1 |
| Kudoh, A | 1 |
| Mizuta, E | 1 |
| Ogura, Y | 1 |
| Sano, A | 1 |
| Oka, M | 1 |
| Ishibashi, K | 1 |
| Umehara, A | 1 |
| Watanabe, K | 1 |
| Ogawa, K | 1 |
| Toyokawa, A | 1 |
| Tsujimura, T | 1 |
| Hamabe, Y | 1 |
| Sato, S | 1 |
| Mukubou, H | 1 |
| Wakahara, T | 1 |
| Kaji, M | 1 |
| Tsukamoto, T | 1 |
| Wakita, K | 1 |
| Onishi, N | 1 |
| Ishida, T | 1 |
| Watanabe, A | 1 |
| Fujiwara, H | 1 |
| Mukai, H | 1 |
| Paillot, B | 1 |
| Priou, F | 1 |
| Jacob, JH | 1 |
| Hebbar, M | 1 |
| Bordenave, S | 1 |
| Cvitkovic, F | 1 |
| Dorval, E | 1 |
| Malek, K | 1 |
| Tonelli, D | 1 |
| Goyle, S | 1 |
| Maraveyas, A | 1 |
| Ogawa, T | 2 |
| Makita, F | 1 |
| Tanahashi, Y | 1 |
| Ohya, T | 1 |
| Tomizawa, N | 1 |
| Satoh, Y | 1 |
| Kobayashi, I | 1 |
| Izumi, M | 1 |
| Hamada, K | 1 |
| Minaguchi, S | 1 |
| Togo, Y | 1 |
| Toshihiko, T | 1 |
| Koyama, T | 1 |
| Kamio, M | 1 |
| Maeda, Y | 3 |
| Makuuchi, H | 6 |
| Murayama, C | 3 |
| Abad, A | 3 |
| Ward, SE | 1 |
| Marples, M | 1 |
| Orr, B | 1 |
| Seymour, MT | 1 |
| Iwamoto, S | 1 |
| Yoshioka, K | 1 |
| Mizuno, H | 1 |
| Ito, T | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Iwamoto, T | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Iwase, K | 1 |
| Segura, C | 1 |
| Afchain, P | 1 |
| de Gramont, A | 2 |
| Saletti, P | 1 |
| Cavalli, F | 1 |
| Morel, A | 1 |
| Boisdron-Celle, M | 2 |
| Fey, L | 1 |
| Lainé-Cessac, P | 1 |
| Gamelin, E | 4 |
| Lin, PC | 1 |
| Chen, WS | 1 |
| Chao, TC | 1 |
| Yang, SH | 1 |
| Tiu, CM | 1 |
| Liu, JH | 1 |
| Sheikh, HY | 1 |
| Valle, JW | 1 |
| Palmer, K | 1 |
| Sjursen, A | 1 |
| Craven, O | 1 |
| Wilson, G | 1 |
| Swindell, R | 1 |
| Saunders, MP | 1 |
| Buzzoni, R | 1 |
| Mariani, L | 1 |
| Zilembo, N | 1 |
| Ferrario, E | 1 |
| Lo Vullo, S | 1 |
| Aitini, E | 1 |
| Isa, L | 1 |
| Barone, C | 1 |
| Jacobelli, S | 1 |
| Recaldin, E | 1 |
| Pinotti, G | 1 |
| Iop, A | 1 |
| Zhou, ZW | 1 |
| Wang, GQ | 1 |
| Wan, de S | 1 |
| Lu, ZH | 1 |
| Chen, YB | 1 |
| Li, S | 1 |
| Chen, G | 1 |
| Pan, ZZ | 1 |
| Tokunaga, Y | 1 |
| Sasaki, H | 1 |
| Saito, T | 1 |
| Almond, J | 1 |
| Ralston, S | 1 |
| Delord, JP | 1 |
| Husseini, F | 1 |
| Desseigne, F | 1 |
| Faroux, R | 1 |
| Piedbois, P | 1 |
| Naman, H | 1 |
| Bugat, R | 1 |
| Etienne-Grimaldi, MC | 2 |
| Cardot, JM | 2 |
| Renée, N | 3 |
| Milano, G | 3 |
| van den Donk, M | 1 |
| Pellis, L | 1 |
| Crott, JW | 1 |
| van Engeland, M | 1 |
| Friederich, P | 1 |
| Nagengast, FM | 1 |
| van Bergeijk, JD | 1 |
| de Boer, SY | 1 |
| Kok, FJ | 1 |
| Keijer, J | 1 |
| Kampman, E | 1 |
| Okamura, S | 1 |
| Narahara, H | 1 |
| Uedo, N | 1 |
| Ishihara, R | 1 |
| Gotoh, M | 1 |
| Takiuchi, H | 1 |
| Château, Y | 1 |
| Ishikawa, K | 2 |
| Tanaka, Y | 1 |
| Yasuda, S | 3 |
| Isogai, A | 1 |
| Nagaya, M | 1 |
| Matsuoka, H | 1 |
| Tsukikawa, S | 3 |
| Kubota, S | 1 |
| Luo, W | 1 |
| Popa, EC | 1 |
| Lyman, BT | 1 |
| Mulcahy, M | 1 |
| Beatty, PA | 1 |
| Geboes, K | 1 |
| Thomas, HR | 1 |
| Ezzeldin, HH | 1 |
| Guarcello, V | 1 |
| Mattison, LK | 1 |
| Fridley, BL | 1 |
| Scalamogna, R | 1 |
| Brugnatelli, S | 1 |
| Tinelli, C | 1 |
| Sagrada, P | 1 |
| Gattoni, E | 1 |
| Tronconi, MC | 1 |
| Riccardi, A | 1 |
| Luchena, G | 1 |
| Corazza, GR | 1 |
| Ushijima, M | 1 |
| Murakami, H | 1 |
| Fukushima, T | 2 |
| Hosotaki, K | 1 |
| Tabira, Y | 1 |
| Shimamoto, M | 1 |
| Tamori, Y | 1 |
| Okabayashi, K | 1 |
| Hasegawa, H | 1 |
| Ishii, Y | 1 |
| Endo, T | 1 |
| Ochiai, H | 1 |
| Kubota, T | 1 |
| Kitagawa, Y | 1 |
| Sotos, GA | 1 |
| Grogan, L | 1 |
| Allegra, CJ | 1 |
| Hirata, K | 1 |
| Omura, K | 2 |
| Kawakami, K | 2 |
| Kanehira, E | 1 |
| Nagasato, A | 1 |
| Kawashima, S | 1 |
| Tawaraya, K | 1 |
| Watanabe, S | 1 |
| Hirano, K | 1 |
| Shirasaka, T | 1 |
| Nakasaki, H | 1 |
| Hanaue, H | 1 |
| Fujii, K | 1 |
| Tajima, T | 3 |
| Mitomi, T | 2 |
| Kurosawa, T | 1 |
| Saltz, LB | 2 |
| Young, CW | 1 |
| Muggia, FM | 1 |
| Conti, JA | 1 |
| Spiess, T | 1 |
| Jeffers, S | 1 |
| Leichman, LP | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Yamamura, T | 4 |
| Oikawa, H | 1 |
| Hanai, A | 2 |
| Matsuzaki, H | 1 |
| Akaishi, O | 1 |
| Seo, K | 1 |
| Kikuchi, K | 1 |
| Ozasa, T | 1 |
| Moriguchi, M | 1 |
| Seki, N | 1 |
| Higaki, T | 1 |
| Oishi, H | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Pazdur, R | 11 |
| Rhodes, V | 1 |
| Ajani, JA | 1 |
| Sugarman, SM | 1 |
| Patt, YZ | 1 |
| Jones, DV | 1 |
| Markowitz, AB | 1 |
| Bready, B | 2 |
| Ashikaga, K | 1 |
| Kimura, C | 1 |
| Kuroda, H | 1 |
| Ono, M | 1 |
| Yoshikawa, K | 1 |
| Hashimoto, T | 2 |
| Dousei, T | 1 |
| Moriguchi, S | 1 |
| Taniguchi, M | 1 |
| Ueda, H | 1 |
| Taketani, S | 1 |
| Suhara, H | 1 |
| Rustum, YM | 4 |
| Shimoyama, T | 3 |
| Kusano, H | 3 |
| Ishikawa, H | 5 |
| Miyashita, K | 1 |
| Nakazaki, T | 1 |
| Yasutake, T | 1 |
| Yoshida, A | 1 |
| Fujita, F | 2 |
| Fujita, M | 2 |
| Inaba, H | 1 |
| Taguchi, T | 3 |
| Ishida, F | 1 |
| Matsu, T | 1 |
| Adachi, I | 1 |
| Bibby, MC | 1 |
| Double, JA | 1 |
| McCormick, JE | 1 |
| McElhinney, RS | 1 |
| Radacic, M | 1 |
| Pratesi, G | 1 |
| Dumont, P | 1 |
| Baccanari, DP | 1 |
| Joyner, SS | 1 |
| Davis, ST | 1 |
| Michiwa, Y | 1 |
| Yagi, H | 1 |
| Fushida, S | 1 |
| Fugimura, T | 1 |
| Sugiyama, K | 1 |
| Kanno, M | 1 |
| Yonemura, Y | 2 |
| Miwa, K | 2 |
| Miyazaki, I | 2 |
| de la Gándara, I | 1 |
| Espinosa, E | 2 |
| Colmenarejo, A | 2 |
| Martínez-Martínez, B | 1 |
| Blanco, E | 2 |
| Juárez, F | 2 |
| Garrido, P | 1 |
| Akao, S | 2 |
| Iwami, N | 2 |
| Oya, M | 1 |
| Terada, H | 1 |
| Kiumi, F | 2 |
| Ikeda, E | 1 |
| Okuda, M | 1 |
| González Barón, M | 1 |
| Garcia Girón, C | 1 |
| Espinosa, J | 1 |
| Martinez, B | 1 |
| Crespo, MC | 1 |
| Ordóñez, A | 1 |
| de Castro, J | 1 |
| Diaz-Canton, E | 1 |
| Ho, DH | 1 |
| Sakamoto, S | 2 |
| Kawachi, Y | 2 |
| Iwama, T | 2 |
| Tsukada, K | 1 |
| Sagara, T | 2 |
| Murakami, S | 1 |
| Kudo, H | 2 |
| Okayasu, I | 1 |
| Mitsuishi, K | 1 |
| Umeno, T | 1 |
| Tanaka, S | 1 |
| Kimura, H | 1 |
| Fuchino, Y | 1 |
| Tomita, A | 1 |
| Meropol, NJ | 6 |
| Noel, D | 2 |
| Sonnichsen, DS | 2 |
| Birkhofer, MJ | 2 |
| Marcuello, E | 2 |
| Gallén, M | 2 |
| Murad, A | 1 |
| de Andrade, CA | 1 |
| Delfino, C | 1 |
| Arikian, S | 1 |
| Doyle, J | 1 |
| Sinha, N | 1 |
| Punt, CJ | 1 |
| Hohneker, JA | 1 |
| Seki, M | 1 |
| Ohta, H | 1 |
| Azekura, K | 1 |
| Ueno, M | 1 |
| Moroguchi, A | 1 |
| Matsubara, T | 1 |
| Canetta, R | 1 |
| Ferreira, I | 2 |
| Rubiales, AS | 1 |
| del Valle, ML | 1 |
| Brito, RA | 1 |
| Medgyesy, D | 3 |
| Zukowski, TH | 2 |
| Royce, ME | 2 |
| Ravandi-Kashani, F | 1 |
| Rifá, J | 1 |
| Massuti, T | 1 |
| Antón, A | 2 |
| Fernández Martos, C | 1 |
| Ollendorf, D | 1 |
| Imai, S | 1 |
| Mochizuki, F | 1 |
| Komoriyama, H | 1 |
| Kanasugi, K | 1 |
| Hagiwara, M | 1 |
| Adjei, AA | 1 |
| Fujioka, M | 1 |
| Kishi, T | 1 |
| Idezuki, Y | 1 |
| Kamano, T | 1 |
| Guérin-Meyer, V | 1 |
| Delva, R | 1 |
| Lortholary, A | 1 |
| Genevieve, F | 1 |
| Larra, F | 1 |
| Ifrah, N | 1 |
| Robert, J | 1 |
| Ahmed, FY | 1 |
| Johnston, SJ | 1 |
| Cassidy, J | 2 |
| O'Kelly, T | 1 |
| Binnie, N | 1 |
| Murray, GI | 1 |
| van Gennip, AH | 1 |
| Abeling, NG | 1 |
| Knight, S | 1 |
| McLeod, HL | 1 |
| Royce, M | 1 |
| Brito, R | 1 |
| Cvitkovic, E | 1 |
| Bekradda, M | 1 |
| Papamichael, D | 1 |
| Suzuka, I | 1 |
| Izumi, S | 1 |
| Onoda, Y | 1 |
| Shiota, K | 1 |
| Nishihara, M | 1 |
| Nakagawa, J | 1 |
| Shimizu, N | 1 |
| Bukowski, R | 1 |
| Burris, H | 1 |
| O'Rourke, M | 1 |
| Wall, JG | 1 |
| Mani, S | 2 |
| Bonny, T | 1 |
| Levin, J | 3 |
| Hohneker, J | 2 |
| Damjanov, N | 1 |
| Beck, T | 1 |
| Chevlen, EM | 1 |
| O'Rourke, MA | 1 |
| Weaver, CH | 1 |
| Bell, WN | 2 |
| White, R | 1 |
| McGuirt, C | 1 |
| Lokich, J | 1 |
| Thongprasert, S | 1 |
| Maoleekoonpairoj, S | 1 |
| Laohavinij, S | 1 |
| Thavichaigarn, P | 1 |
| Kusunoki, M | 2 |
| Yanagi, H | 2 |
| Noda, M | 2 |
| Yoshikawa, R | 2 |
| Bissett, D | 1 |
| Ahmed, F | 1 |
| McLeod, H | 1 |
| Ohki, S | 1 |
| Otani, Y | 1 |
| Takemiya, S | 1 |
| Nagasaki, H | 1 |
| Nishiyama, K | 1 |
| Hiki, Y | 1 |
| Kumada, K | 1 |
| Shimada, H | 1 |
| Louvet, C | 1 |
| Coudray, AM | 1 |
| Tournigand, C | 1 |
| Prévost, S | 1 |
| Raymond, E | 1 |
| Chazard, M | 2 |
| Gespach, C | 1 |
| Bading, JR | 1 |
| Alauddin, MM | 1 |
| Fissekis, JD | 1 |
| Shahinian, AH | 1 |
| Joung, J | 1 |
| Conti, PS | 1 |
| Guglielmi, A | 1 |
| Grossi, F | 1 |
| Puglisi, F | 1 |
| Aschele, C | 1 |
| Bastian, G | 1 |
| Moutardier, V | 1 |
| Delperro, JR | 1 |
| Fargeot, P | 1 |
| Fraisse, J | 1 |
| Formento, P | 1 |
| Schilling, G | 1 |
| Lipp, R | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Tokunaga, N | 1 |
| Ishizu, K | 1 |
| Lewis, NL | 1 |
| Todnem, K | 1 |
| Harboe, K | 1 |
| Zotova, L | 1 |
| Lind, A | 1 |
| Ogreid, D | 1 |
| Blum, S | 1 |
| Pirie, L | 1 |
| Brand, GM | 1 |
| Shatari, T | 1 |
| Nozawa, K | 1 |
| Dwivedy, S | 1 |
| Haller, D | 1 |
| Furuyama, JI | 1 |
| Hashimoto-Tamaoki, T | 1 |
| Niedzwiecki, D | 1 |
| Hollis, D | 1 |
| Damle, B | 1 |
| Ravandi, F | 1 |
| Kaul, S | 1 |
| Sonnichsen, D | 1 |
| Brooks, D | 1 |
| Stewart, D | 1 |
| Alberts, D | 1 |
| James, RD | 1 |
| Aabo, K | 2 |
| Kameya, T | 1 |
| Iwase, H | 1 |
| Pessi, MA | 1 |
| Poletti, P | 1 |
| Coleman, R | 1 |
| Wilke, H | 1 |
| Reimer, P | 1 |
| Rückle-Lanz, H | 1 |
| Alonso, V | 1 |
| Escudero, P | 1 |
| Zorrilla, M | 1 |
| Isla, MD | 1 |
| Herrero, A | 1 |
| Mayordomo, JI | 1 |
| Martinez-Trufero, J | 1 |
| Sáenz, A | 1 |
| Tres, A | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Sinlarat, P | 1 |
| Lohsiriwat, D | 1 |
| Lert-Akayamanee, N | 1 |
| Nimmanwudipong, T | 1 |
| Srimuninnimit, V | 1 |
| Vathanophas, V | 1 |
| Arch-Yaemsuan, P | 1 |
| Boonnuch, W | 1 |
| Borner, MM | 1 |
| Schoffski, P | 1 |
| de Wit, R | 1 |
| Caponigro, F | 1 |
| Comella, G | 1 |
| Sulkes, A | 1 |
| Greim, G | 1 |
| van der Born, K | 1 |
| Wanders, J | 1 |
| de Boer, RF | 1 |
| Fumoleau, P | 1 |
| West, WH | 1 |
| Wong, A | 1 |
| Colwell, B | 1 |
| Thirlwell, MP | 1 |
| Ansari, RH | 1 |
| White, RL | 1 |
| Yates, BB | 1 |
| McGuirt, PV | 1 |
| Holen, KD | 1 |
| Ohashi, Y | 1 |
| Koike, A | 1 |
| Saji, S | 1 |
| Takagi, H | 1 |
| Nimura, Y | 1 |
| Hasumi, A | 1 |
| Baba, S | 1 |
| Manabe, T | 1 |
| Maruta, M | 1 |
| Croockewit, AJ | 1 |
| de Boer, JE | 1 |
| van Loenhout, JW | 1 |
| Koopmans, PP | 1 |
| Adimi, P | 1 |
| Inaba, S | 1 |
| Kondo, Y | 1 |
| Tsuchiya, K | 1 |
| Kawai, K | 1 |
| Ogino, A | 1 |
| Umeda, T | 1 |
| Ueda, Y | 1 |
| Hirano, T | 3 |
| Eida, K | 3 |
| Ishii, T | 3 |
| Kotake, Y | 3 |
| Tobinaga, K | 1 |
| Nogawa, T | 1 |
| Futami, K | 1 |
| Arima, S | 1 |
| Yoshimura, S | 1 |
| Okamoto, T | 1 |
| Yamasaki, K | 1 |
| Koto, T | 1 |
| Yamasaki, S | 1 |
| Kawahara, K | 1 |
| Ikuno, T | 1 |
| Takeda, S | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| Malik, ST | 1 |
| Talbot, D | 1 |
| Clarke, PI | 1 |
| Osborne, R | 1 |
| Reznek, R | 1 |
| Wrigley, PF | 1 |
| Slevin, ML | 1 |
| Kuwa, K | 1 |
| Kawasaki, T | 1 |
| Kasahara, N | 1 |
| Okamoto, R | 1 |
| Kosaka, T | 1 |
| Takegawa, S | 1 |
| Oyama, S | 1 |
| Fukuda, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)[NCT04737187] | Phase 3 | 492 participants (Actual) | Interventional | 2020-11-25 | Completed | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies[NCT01607957] | Phase 3 | 800 participants (Actual) | Interventional | 2012-06-17 | Completed | ||
| A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
| Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies[NCT01955837] | Phase 3 | 406 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy[NCT02286492] | 0 participants | Expanded Access | Approved for marketing | ||||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments[NCT02500043] | Phase 3 | 507 participants (Actual) | Interventional | 2016-02-24 | Completed | ||
| Aspirin/Folate Prevention of Large Bowel Polyps[NCT00272324] | Phase 2/Phase 3 | 1,121 participants | Interventional | 1992-02-29 | Completed | ||
| A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer[NCT00003254] | Phase 2 | 75 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589] | Phase 3 | 60 participants | Interventional | 2002-12-31 | Completed | ||
| A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer[NCT00004860] | Phase 2 | 0 participants | Interventional | 2000-10-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Objective response was defined as percentage of participants who achieved complete response (CR) or partial response (PR) according to the RECIST version 1.1 and using investigator's tumour assessment. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. (NCT04737187)
Timeframe: From the date of randomization to the date of documentation of progression or death due to any cause or data cut-off, whichever occurred first (i.e., up to 20 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 6.10 |
| Trifluridine/Tipiracil | 1.22 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. (NCT04737187)
Timeframe: From date of randomization to the death due to any cause or cut-ff date, whichever comes first (maximum duration: up to 20 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 10.78 |
| Trifluridine/Tipiracil | 7.46 |
Disease control is defined as percentage of participants who achieved CR or PR, or stable disease (SD) as per RECIST 1.1 and using investigator's tumour assessment from the date of randomization to until disease progression or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. (NCT04737187)
Timeframe: From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 69.51 |
| Trifluridine/Tipiracil | 41.87 |
PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. (NCT04737187)
Timeframe: From randomization to the date of radiological tumour progression or death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 5.55 |
| Trifluridine/Tipiracil | 2.40 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 12 months was reported. (NCT04737187)
Timeframe: From date of randomization until 12 months post treatment
| Intervention | probability of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 0.43 |
| Trifluridine/Tipiracil | 0.30 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 18 months was reported. (NCT04737187)
Timeframe: From date of randomization until 18 months post treatment
| Intervention | probability of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 0.28 |
| Trifluridine/Tipiracil | 0.15 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 6 months was reported. (NCT04737187)
Timeframe: From date of randomization until 6 months post treatment
| Intervention | probability of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 0.77 |
| Trifluridine/Tipiracil | 0.61 |
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs. (NCT04737187)
Timeframe: From Baseline up to 30 days after the last dose of study treatments (i.e., up to 19.5 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| Trifluridine/Tipiracil | 241 | 77 |
| Trifluridine/Tipiracil + Bevacizumab | 241 | 61 |
PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. In this outcome measure, data of PFS at 3 months was reported. (NCT04737187)
Timeframe: From randomization until 3, 6, 9, and 12 months post treatment
| Intervention | probability of participants (Number) | |||
|---|---|---|---|---|
| At 3 Months | At 6 Months | At 9 Months | At 12 Months | |
| Trifluridine/Tipiracil | 0.45 | 0.16 | 0.05 | 0.01 |
| Trifluridine/Tipiracil + Bevacizumab | 0.73 | 0.43 | 0.28 | 0.16 |
Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
| Intervention | months (Median) |
|---|---|
| TAS-102 | 7.1 |
| Placebo | 5.3 |
Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
| Intervention | months (Median) |
|---|---|
| TAS-102 | 2.0 |
| Placebo | 1.7 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs. (NCT01607957)
Timeframe: From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | Any treatment-related AE | Any ≥Grade 3 AE | Any treatment-related ≥Grade 3 AE | Any serious AE (SAE) | Any AE resulting in discontinuation | Any AE with outcome of death | |
| Placebo | 93.2 | 54.7 | 51.7 | 9.8 | 33.6 | 13.6 | 11.3 |
| TAS-102 | 98.3 | 85.7 | 69.4 | 49.0 | 29.6 | 10.3 | 3.2 |
The assessment of DCR paralleled that of ORR, with DCR defined as the proportion of patients with objective evidence of CR, PR, or SD. (NCT01955837)
Timeframe: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
| Intervention | percentage of participants (Number) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 44.1 |
| Placebo | 14.6 |
Duration of response was derived for those patients with objective evidence of PR or CR. Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause. Patients alive and progression free as of the analysis cut-off date were censored at their last evaluable tumor response assessment prior to initiation of any non-study cancer treatment. (NCT01955837)
Timeframe: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
| Intervention | Months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 6.6 |
| Placebo | 0 |
"The assessment of ORR was based on Investigator review of the images according to RECIST Version 1.1. Overall response rate was defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR). At the analysis stage, the best overall response was assigned for each patient as the best response recorded from all responses recorded after study randomization. If applicable, responses recorded after disease progression or initiation of non-study cancer treatment was excluded. A patient's best response assignment of stable disease (SD) needed to be maintained for at least 6 weeks after study randomization. If a patient didn't meet this condition, best response was assigned Not evaluable." (NCT01955837)
Timeframe: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
| Intervention | percentage of participants (Number) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 1.1 |
| Placebo | 0.0 |
The primary endpoint was Overall Survival (OS), which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. (NCT01955837)
Timeframe: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
| Intervention | Months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 7.8 |
| Placebo | 7.1 |
"The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier.~The OS indicated above as secondary outcome was analyzed by mutant type KRAS." (NCT01955837)
Timeframe: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
| Intervention | months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 7.0 |
| Placebo | 6.5 |
"The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier.~The OS indicated above as secondary outcome was analyzed by wild type KRAS." (NCT01955837)
Timeframe: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
| Intervention | months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 8.6 |
| Placebo | 7.4 |
Tumor assessments were performed throughout the study period and analyzed using Response Evaluation Criteria in Solid Tumors criteria (Version 1.1, 2009). Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. (NCT01955837)
Timeframe: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
| Intervention | Months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 2.0 |
| Placebo | 1.8 |
Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by mutant type KRAS. (NCT01955837)
Timeframe: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
| Intervention | Months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 2.2 |
| Placebo | 1.8 |
Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by wild type KRAS. (NCT01955837)
Timeframe: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
| Intervention | months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 2.0 |
| Placebo | 1.8 |
Time to treatment failure was defined as the time (in months) from the date of randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause. Censoring for TTF was also applied for those patients who were given non-study cancer treatment, with censoring at the time when the patient began the non-study cancer treatment. (NCT01955837)
Timeframe: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
| Intervention | months (Median) |
|---|---|
| TAS-102（Trifluridine/Tipiracil） | 1.9 |
| Placebo | 1.8 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs. (NCT01955837)
Timeframe: From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No AEs | One or more AEs | One or more TEAEs | TEAE severity by CTCAE grade:Grade1 | TEAE severity by CTCAE grade:Grade2 | TEAE severity by CTCAE grade:Grade3 | TEAE severity by CTCAE grade:Grade4 | TEAE severity by CTCAE grade:Grade5 | TEAE causality(Related) | TEAE causality(Not Related) | One or more TEAEs leading to discontinuation | One or more SAEs | One or more TESAEs | One or more TEAEs leading to death | |
| Placebo | 15 | 120 | 118 | 32 | 41 | 33 | 11 | 1 | 70 | 48 | 13 | 32 | 31 | 1 |
| TAS-102（Trifluridine/Tipiracil） | 2 | 269 | 269 | 23 | 84 | 127 | 30 | 5 | 244 | 25 | 27 | 63 | 63 | 5 |
All laboratory values that were out of the normal range were to be evaluated for their clinical significance before exposing the patient to the next dose of study medication. Any laboratory abnormality that was clinically significant, e.g., results in delay of study medication dosing, study discontinuation, required treatment due to abnormal values, or was considered by the Investigator to be medical important, were to be reported as an AE, unless it was considered part of clinical manifestations to a clinical diagnosis that has already been reported as an AE. (NCT01955837)
Timeframe: From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia：Any Grade | Anemia：Grade >=3 | Leukopenia：Any Grade | Leukopenia：Grade >=3 | Neutropenia：Any Grade | Neutropenia：Grade >=3 | Lymphopenia：Any Grade | Lymphopenia：Grade >=3 | Thrombocytopenia：Any Grade | Thrombocytopenia：Grade >=3 | Lymphocytosis：Any Grade | Lymphocytosis：Grade >=3 | Increase in alkaline phosphatase level：Any Grade | Increase in alkaline phosphatase level：Grade >=3 | Hyperglycemia：Any Grade | Hyperglycemia：Grade >=3 | Increase in total bilirubin level：Any Grade | Increase in total bilirubin level：Grade >=3 | Hypoalbuminemia：Any Grade | Hypoalbuminemia：Grade >=3 | Hyponatremia：Any Grade | Hyponatremia：Grade >=3 | Hypocalcemia：Any Grade | Hypocalcemia：Grade >=3 | Increase in AST level：Any Grade | Increase in AST level：Grade >=3 | Increase in ALT level：Any Grade | Increase in ALT level：Grade >=3 | Hypokalemia：Any Grade | Hypokalemia：Grade >=3 | Increase in creatinine level：Any Grade | Increase in creatinine level：Grade >=3 | Hyperkalemia：Any Grade | Hyperkalemia：Grade >=3 | Hypercalcemia：Any Grade | Hypercalcemia：Grade >=3 | |
| Placebo | 52 | 8 | 4 | 0 | 1 | 0 | 34 | 3 | 10 | 2 | 1 | 0 | 58 | 5 | 50 | 3 | 28 | 10 | 44 | 0 | 38 | 6 | 33 | 1 | 40 | 7 | 29 | 4 | 11 | 1 | 10 | 0 | 10 | 0 | 1 | 1 |
| TAS-102（Trifluridine/Tipiracil） | 209 | 48 | 190 | 56 | 182 | 90 | 146 | 39 | 96 | 8 | 4 | 1 | 91 | 11 | 98 | 7 | 99 | 19 | 78 | 8 | 81 | 12 | 77 | 3 | 63 | 10 | 48 | 3 | 31 | 2 | 13 | 3 | 11 | 1 | 8 | 0 |
DCR was defined as the proportion of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD). The assessment of DCR was based on Investigator review of radiologic images and following RECIST criteria (version 1.1, 2009). (NCT02500043)
Timeframe: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| TAS-102+BSC | 44.1 |
| Placebo+BSC | 14.5 |
"Overall response rate was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR).~CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to < 10 mm.~PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference." (NCT02500043)
Timeframe: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| TAS-102+BSC | 4.5 |
| Placebo+BSC | 2.1 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death were censored at last follow-up or cut-off date, whichever comes first. OS was estimated by Kaplan-Meier method. (NCT02500043)
Timeframe: From the date of randomization to the data cut-off date (maximum duration: up to approximately 46 months)
| Intervention | months (Median) |
|---|---|
| TAS-102+BSC | 5.7 |
| Placebo+BSC | 3.6 |
PFS was defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for target lesions were defined as target lesions with at least 20 % relative increase in the sum of diameters with reference to the smallest sum on study, including the baseline sum and this sum demonstrated an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions or Unequivocal progression of existing non-target lesions. All alive participants with no disease progression as of the analysis cut-off date were censored at the last tumor assessment. PFS was estimated by Kaplan-Meier method. (NCT02500043)
Timeframe: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months)
| Intervention | months (Median) |
|---|---|
| TAS-102+BSC | 2.0 |
| Placebo+BSC | 1.8 |
The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0 = normal activity; 1= symptoms but ambulatory; 2= in bed for < 50% of the time; 3= in bed for > 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as a change from 0, 1 to >=2, or from 2 to >=3. (NCT02500043)
Timeframe: At the time of randomization (Day 1 Cycle 1) and within 24 hours prior to start of study treatment in every cycle (maximum duration: up to approximately 46 months)
| Intervention | months (Median) |
|---|---|
| TAS-102+BSC | 4.3 |
| Placebo+BSC | 2.3 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) and other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health and QoL, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 and 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best QoL for participant. (NCT02500043)
Timeframe: Baseline, Day 1 Cycle 2 up to end of treatment (EOT) (within 30 days of last study treatment) and 30-Day safety follow-up visit (maximum duration: up to approximately 46 months)
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | Cycle 7 | Cycle 8 | Cycle 9 | Cycle 10 | Cycle 11 | Cycle 12 | Cycle 13 | Last Collection Cycle | Safety Follow-Up | |
| TAS-102+BSC | -2.7 | -5.9 | -4.1 | -3.6 | -5.9 | -8.8 | -9.5 | -4.3 | 2.4 | -14.4 | -16.7 | -8.3 | 0.0 | -8.8 | -16.5 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) and other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health and QoL, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 and 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best QoL for participant. (NCT02500043)
Timeframe: Baseline, Day 1 Cycle 2 up to end of treatment (EOT) (within 30 days of last study treatment) and 30-Day safety follow-up visit (maximum duration: up to approximately 46 months)
| Intervention | units on a scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | Cycle 7 | Cycle 8 | Cycle 9 | Cycle 10 | Cycle 11 | Cycle 12 | Cycle 13 | Cycle 14 | Cycle 15 | Last Collection Cycle | Safety Follow-Up | |
| Placebo+BSC | -5.9 | -7.3 | -1.4 | -1.7 | 11.1 | 15.6 | 20.0 | 16.7 | 16.7 | 25.0 | 25.0 | 33.3 | 33.3 | 33.3 | 33.3 | -9.8 | -8.9 |
The Quality of Life Questionnaire Stomach Cancer Module 22 (QLQ-STO22) assessed symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, dietary restrictions, pain QS22, reflux, and anxiety) and 4 single items (dry mouth, hair loss, taste problems, body image). Most questions use 4-point scale (1='Not at all', 2=a little, 3=quite a bit and 4='Very much'). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100, where higher score=better level of functioning or greater degree of symptoms. (NCT02500043)
Timeframe: Baseline, Cycle 1 Day 1 up to end of treatment (EOT) (within 30 days of last study treatment) (maximum duration: up to approximately 46 months)
| Intervention | percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dysphagia | Dietary Restrictions | Pain QS22 | Reflux | Anxiety | Dry Mouth | Body Image | Hair Loss | Taste Problems | |
| Placebo+BSC | 78.2 | 78.2 | 78.2 | 78.2 | 78.2 | 78.2 | 78.2 | 78.2 | 78.2 |
| TAS-102+BSC | 86.6 | 86.6 | 86.6 | 86.6 | 86.6 | 86.4 | 85.8 | 86.6 | 86.6 |
Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study medication was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs/TESAEs were defined as events that started on or after treatment or started before treatment and worsened after the start of treatment through 30 days after the last dose of study treatment. (NCT02500043)
Timeframe: From the first dose of study treatment until 30 days after the last dose of study treatment (maximum duration: up to approximately 46 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| Placebo+BSC | 151 | 70 |
| TAS-102+BSC | 319 | 143 |
81 reviews available for uracil and Colorectal Cancer
| Article | Year |
|---|---|
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Onc | 2022 |
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Front | 2023 |
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms | 2019 |
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disea | 2020 |
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2020 |
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Colorectal Neoplasms; Double-Blind Me | 2020 |
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuva | 2017 |
A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Network Meta-Analysis; Pheny | 2018 |
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrro | 2018 |
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neopla | 2018 |
The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Co | 2018 |
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resist | 2019 |
The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dose | 2019 |
[Efficacy of TAS-102].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Py | 2015 |
TAS-102 for the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Com | 2015 |
Current and advancing treatments for metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2016 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Huma | 2016 |
[Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)].
Topics: Animals; Cell Cycle; Colorectal Neoplasms; DNA; Drug Combinations; Drug Design; Drug Resistance, Neo | 2016 |
TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
Review on TAS-102 development and its use for metastatic colorectal cancer.
Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Th | 2016 |
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Randomized Con | 2016 |
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 2017 |
The role of UFT in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Tegafur; Uracil | 2009 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
The nature of enzymes involved in uracil-DNA repair: isoform characteristics of proteins responsible for nuclear and mitochondrial genomic integrity.
Topics: Amino Acid Sequence; Colorectal Neoplasms; DNA Glycosylases; DNA Repair; Humans; Isoenzymes; Mitocho | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; | 2001 |
[Progress in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh | 2003 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2003 |
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[Tegafur.uracil for treatment of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug R | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[Effect of systemic chemotherapy by 5-FU with low dose CDDP (in the hospital) and UFT with low dose CDDP (in outpatient clinic) in unresectable recurrent colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycyt | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2003 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Hu | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deo | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
[Adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug C | 2006 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capeci | 2006 |
Metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2006 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Com | 2007 |
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neopla | 1994 |
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop | 1995 |
Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 1996 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 1998 |
Clinical development of eniluracil: current status.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 1998 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neopla | 1999 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 1999 |
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Prodrugs; Thym | 1999 |
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
Oral therapy for colorectal cancer: how to choose.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availabilit | 2000 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 2000 |
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans; | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
[Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cl | 2000 |
UFT in the treatment of colorectal and breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplas | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2001 |
New drugs and combinations in the palliative treatment of colon and rectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colo | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2001 |
Answering patients' needs: oral alternatives to intravenous therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria | 2001 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2002 |
137 trials available for uracil and Colorectal Cancer
| Article | Year |
|---|---|
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Fema | 2022 |
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Fema | 2022 |
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Fema | 2022 |
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Fema | 2022 |
A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2023 |
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Pro | 2023 |
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Ne | 2023 |
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2019 |
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Japan; Neutropenia; Pyrrolidines; Thymine; Trifluri | 2020 |
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Protocols; Colorectal Neoplasm | 2020 |
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combin | 2020 |
Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2018 |
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Colorectal Neoplasms; Disease-Fre | 2017 |
MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disea | 2018 |
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; C | 2018 |
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2018 |
The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2018 |
Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Double- | 2018 |
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Respon | 2018 |
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2013 |
[Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined | 2013 |
[Treatment outcome of peptide vaccination for advanced colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Female; | 2013 |
Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian | 2015 |
A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deo | 2014 |
Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final r
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2014 |
[Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Female; | 2014 |
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Comb | 2015 |
TAS-102 for metastatic refractory colorectal cancer.
Topics: Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Neoplasm Metas | 2015 |
Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2015 |
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorec | 2015 |
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2015 |
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2016 |
Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Mismatch Repair; Female; Genes, ras; | 2016 |
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Colorectal Neoplasms; Double-Blind Method; Drug Co | 2017 |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Colorectal Neoplasms; Double-Blind Method; Drug Co | 2017 |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Colorectal Neoplasms; Double-Blind Method; Drug Co | 2017 |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Colorectal Neoplasms; Double-Blind Method; Drug Co | 2017 |
Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2016 |
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
Topics: Aged; Colon; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; | 2017 |
Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2008 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2009 |
Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; | 2009 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
[Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Col | 2011 |
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Female | 2012 |
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2012 |
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2013 |
Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorecta | 2002 |
Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2001 |
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Colorectal Ne | 2002 |
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2003 |
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Female; Humans; K | 2003 |
Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; C | 2003 |
Pre- and post-operative adjuvant chemotherapy in colorectal cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Mid | 2003 |
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Dihy | 2003 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2004 |
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ad | 2004 |
Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cross-Over Studie | 2005 |
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe | 2005 |
Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2005 |
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; CD57 Antigens; CD8 Antig | 2006 |
[Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chem | 2006 |
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2007 |
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2007 |
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 2007 |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2008 |
Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; DNA Methylation; Erythrocytes; Fem | 2007 |
Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; An | 2007 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Combined Modalit | 2007 |
Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2007 |
Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2008 |
Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Color | 1995 |
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
[Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorect | 1995 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1994 |
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1994 |
[Evaluation of preoperative chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1996 |
Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colore | 1995 |
[Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 1996 |
Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 1997 |
Phase II study of UFT plus leucovorin in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Combinations; | 1997 |
UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Leu | 1997 |
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations | 1997 |
[Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy | 1997 |
Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorecta | 1997 |
UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug C | 1997 |
5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca.
Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combina | 1997 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi | 1999 |
UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1999 |
Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 1999 |
Impact of uracil/tegafur plus oral calcium folinate on resource utilization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1999 |
UFT plus calcium folinate/irinotecan in colorectal cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Campt | 1999 |
Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1999 |
[Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1999 |
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chi-Square Distribution; Chromatogra | 1999 |
Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
Topics: Adenocarcinoma; Administration, Oral; Aged; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP) | 1999 |
[Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1999 |
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Ne | 2000 |
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2000 |
Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Color | 2000 |
Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2000 |
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplas | 2000 |
UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Therapy, Com | 2000 |
Impact of UFT on tumoral TS and DPD levels in colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Di | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
UFT plus leucovorin for metastatic colorectal cancer: Japanese experience.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2001 |
Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coh | 2001 |
Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; | 2001 |
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2002 |
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2002 |
Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorecta | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
[Multihospital randomized study on pre- and post-operative adjuvant chemotherapy for colorectal cancer (Part 2)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1991 |
198 other studies available for uracil and Colorectal Cancer
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Prognosis; Pyrro | 2021 |
Selective sensing of the nucleoside analogue, trifluridine and tipiracil in dosage form and biological matrices.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Nuc | 2022 |
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prog | 2022 |
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm | 2022 |
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic | 2022 |
Regorafenib and trifluridine/tipiracil in real clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Mal | 2022 |
Regorafenib and trifluridine/tipiracil in real clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Mal | 2022 |
Regorafenib and trifluridine/tipiracil in real clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Mal | 2022 |
Regorafenib and trifluridine/tipiracil in real clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Mal | 2022 |
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; | 2023 |
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Topics: Adult; Aged; Canada; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Frontotem | 2022 |
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2023 |
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Topics: Administration, Oral; Animals; Colorectal Neoplasms; Fluorouracil; Rats; Tegafur; Uracil | 2023 |
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
N2 Lymph Node Metastasis Is a Useful Predictor of Recurrence in Patients With Stage III Rectal Cancer Undergoing Adjuvant Chemotherapy Using Tegafur-uracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2023 |
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotempo | 2023 |
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Topics: Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Japan; Retros | 2023 |
Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2023 |
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Ram | 2023 |
Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2023 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2023 |
Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Canada; Colorectal Neop | 2019 |
Sequencing beyond the second-line setting in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo | 2019 |
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Kaplan-Meier E | 2020 |
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine; U | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2020 |
5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Colorectal Neoplasms; Femal | 2020 |
Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2020 |
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colorectal Neoplasms; Drug Combinations; | 2020 |
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Colorectal Neoplasms | 2019 |
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.
Topics: Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; England; Humans; Pyrrolidines; Thymi | 2020 |
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2021 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo | 2020 |
Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chroma | 2021 |
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2021 |
Lonsurf (trifluridine/tipiracil): Assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Co | 2021 |
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Topics: Colorectal Neoplasms; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Retr | 2021 |
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; | 2017 |
A new sample preparation and separation combination for the precise, accurate, and simultaneous determination of uracil and dihydrouracil in human plasma by reversed-phase HPLC.
Topics: Calibration; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Humans; Reproducibility of | 2017 |
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2018 |
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Agents; California; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; E | 2017 |
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Anal | 2018 |
Integrated safety summary for trifluridine/tipiracil (TAS-102).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal | 2018 |
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone Marrow Cells; Colorectal Neoplasms; DNA; | 2017 |
TAS-102 in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2018 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Pyrrolidines; Thymine; Trifluridine; Ura | 2018 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; | 2018 |
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
Topics: Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Humans; Progression-Free Survival; Pyr | 2018 |
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2018 |
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Italy; Male | 2018 |
Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Drug Combinations; Dr | 2018 |
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2018 |
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; | 2018 |
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2018 |
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Colorec | 2018 |
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Fem | 2018 |
Defective repair capacity of variant proteins of the DNA glycosylase NTHL1 for 5-hydroxyuracil, an oxidation product of cytosine.
Topics: Adenomatous Polyposis Coli; Alleles; Cell Line, Tumor; Colorectal Neoplasms; Deoxyribonuclease (Pyri | 2019 |
Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; | 2019 |
Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2019 |
Detection and Application of 5-Formylcytosine and 5-Formyluracil in DNA.
Topics: Biomarkers, Tumor; Colorectal Neoplasms; Cytosine; DNA; Fluorescent Dyes; Humans; Mass Spectrometry; | 2019 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Animals; Antimetabolites, Antineoplastic; Autophagy; B | 2019 |
Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD3 Co | 2019 |
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects a | 2020 |
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Hum | 2019 |
Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; | 2019 |
Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); | 2013 |
Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colon; Colorectal Neoplasms; Dihydroura | 2013 |
A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Deh | 2013 |
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2014 |
Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.
Topics: Animals; Breast Neoplasms; Colorectal Neoplasms; Coumarins; Female; HCT116 Cells; Humans; Lactic Aci | 2014 |
Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemothe | 2013 |
Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; | 2014 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells.
Topics: Animals; Caco-2 Cells; Carrier Proteins; Cell Line, Tumor; Cell Membrane Permeability; Colorectal Ne | 2015 |
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Drug Combinations; Equilibrati | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
TAS-102 prolongs overall survival in refractory colorectal cancer, study shows.
Topics: Adenocarcinoma; Colorectal Neoplasms; Female; Humans; Male; Trifluridine; Uracil | 2015 |
Drug Improves Survival in Refractory Colorectal Cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; | 2015 |
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
[Short-Term Outcome of TAS-102 for Refractory Metastatic Colorectal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middl | 2015 |
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; | 2016 |
[Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2016 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2016 |
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
In brief: trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Fema | 2016 |
TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
Topics: Cardiotoxicity; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Treatment Ou | 2016 |
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Clinical Trials, | 2016 |
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug | 2016 |
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Fema | 2017 |
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Capecit | 2017 |
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Combi | 2017 |
Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Japan; Lung Diseases, Inters | 2016 |
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Chromatography, High Pressure Liquid; Colo | 2009 |
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2008 |
[Three cases of complete response after treatment with UFT and leucovorin for recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 2008 |
Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2009 |
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2009 |
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2009 |
Uracil misincorporation into DNA and folic acid supplementation.
Topics: Adenoma; Aged; Alcohol Drinking; Aspirin; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; DN | 2010 |
Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined | 2010 |
A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relatio | 2010 |
Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2010 |
[Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2010 |
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Gene Frequency; Glucuronosyltr | 2011 |
[European Organization for Research and Treatment of Cancer QLQ-C30 and functional assessment of cancer therapy- general for measurement of quality of life in colorectal cancer patients who received adjuvant chemotherapy- a comparison].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2010 |
[Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2010 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2012 |
LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Chromatography, Liquid; Colorectal Neoplasms; Drug Monitoring | 2013 |
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2012 |
TAS-102 in refractory colorectal cancer: caution is needed.
Topics: Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Pyrrolidines; Thymine; Trifluridine; | 2012 |
TAS-102: more than an antimetabolite.
Topics: Colorectal Neoplasms; Female; Humans; Male; Trifluridine; Uracil | 2012 |
[Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Female; | 2012 |
Of what value is uracil/tegafur plus leucovorin to colorectal cancer patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Approval; Health Services | 2002 |
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Syne | 2002 |
[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Canada; Clinical Trials, Phase III as T | 2003 |
Oral tegafur-uracil plus leucovorin in metastatic colorectal cancer: clinical insights. Proceedings of a roundtable expert meeting. October 2002, Nice, France.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Leucovorin; | 2003 |
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2003 |
[Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Apoptosis; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
Vitamin B-12 deficiency induces anomalies of base substitution and methylation in the DNA of rat colonic epithelium.
Topics: Animals; Body Weight; Colon; Colorectal Neoplasms; DNA; DNA Methylation; Epithelium; Folic Acid; Gas | 2004 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2004 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal Neopl | 2004 |
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans; Neoplasm Staging; Proteoglycans; Tegafur; Urac | 2004 |
Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Colorectal Neoplasms; DNA Damage; DNA Methylat | 2004 |
[Variation of cytokines with administration of chemotherapeutic and immuno-therapeutic drugs for colorectal cancer].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cytoki | 2004 |
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2004 |
[Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2005 |
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
[Usefulness in predicting parameters for the selection of responders who received immunochemotherapy with PSK in patients with colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; CD4-Positive T-Lymphocytes; Colorectal | 2005 |
[Hepatic arterial infusion (HAI) chemotherapy achieved a complete response (CR) for multiple liver metastases of colorectal cancer--two case reports].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2005 |
[Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials | 2005 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
[Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
Topics: Adenine; Aged; Alleles; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Ana | 2007 |
Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2007 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Breath Tests; Chromatography, High Pressure Liqui | 2007 |
UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2007 |
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2007 |
[Two cases of recurrent colorectal cancer treated successfully with folinate/tegafur/uracil (UFT/LV) chemotherapy on an outpatient basis].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal | 2008 |
The number of 5-fluoro-2'-deoxyuridine-5'-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment.
Topics: Base Sequence; Binding Sites; Colorectal Neoplasms; Fluorodeoxyuridylate; Humans; Molecular Sequence | 1995 |
Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer.
Topics: Animals; Colorectal Neoplasms; Fluorouracil; Infusions, Intravenous; Liver Neoplasms; Male; Mice; Mi | 1994 |
[Portal-transfer of an orally administered anti-cancer agent analysis of the time course of portal blood and systemic blood levels of preoperatively administered UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 1994 |
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1994 |
[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Changes of the number of FdUMP binding sites of thymidylate synthase and folate pools in human colorectal carcinomas following the administration of tegafur and uracil: preliminary report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Colorectal Neoplasms; Fluorodeoxyurid | 1993 |
Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5-substituent and the point of attachment (N1 or N3) of the uracil moiety in seco-nucleoside nitrosoureas.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; Lung Neoplasms; Male; Mammary Neoplasm | 1993 |
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme | 1995 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1997 |
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Differentiatio | 1997 |
A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
Topics: Argentina; Brazil; Chemotherapy, Adjuvant; Colorectal Neoplasms; Costs and Cost Analysis; Drug Combi | 1997 |
Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1998 |
[Tegafur/uracil and oral calcium folinate in colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Tegafur; Uracil | 1998 |
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Clinical Trials as Topi | 1999 |
[Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorectal Neoplasms; Drug Administrati | 1999 |
[UFT-E granule compliance in postoperative adjuvant chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colorectal Neoplasms; Drug C | 2000 |
Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorine | 2000 |
A novel weekday-on/weekend-off UFT schedule.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells.
Topics: Aged; Antigens, Polyomavirus Transforming; Cells, Cultured; Colon; Colorectal Neoplasms; Culture Med | 2000 |
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2001 |
A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; D | 2001 |
Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Capsule instead of infusion--new oral chemotherapy option].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1992 |
[Electron microscopic study on the method of evaluation of SRC assay].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Evaluation | 1992 |
[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1991 |
[Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon; Colorectal Neoplasms; | 1991 |
[Relationship between antitumor activity and the inhibition of thymidylate synthase after oral administration of UFT in nude mice bearing human tumor].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cel | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
Phase II trial of UFT in advanced colorectal and gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1990 |
[Effects of neo-adjuvant chemotherapy with UFT (a combination of tegafur and uracil) on DNA-synthesizing enzyme activities in human colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Depression, Chemical; Humans; | 1989 |
[Effect of UFT on nuclear DNA distribution of gastric and colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm; Humans; Stomach | 1989 |
[Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Postoper | 1988 |